DMID Protocol 20- 0012  Version 5.0 
Apramycin  10 July 2023  
 
A PHASE I, OPEN- LABEL STUDY TO ASSESS LUNG 
PHARMACOKINETICS AND SAFETY OF A SINGLE DOSE OF 
APRAMYCIN ADMINISTERED INTRAVENOUSLY IN 
HEALTHY ADULT SUBJECTS  
 
 DMID Protocol Number:  20-0012  
 
DMID Funding Mechanism:  Phase 1 Clinical Trial Unit s 
 
Pharmaceutical Support : Juvabis AG  
 
IND Sponsor:  Division of Microbiology and Infectious Diseases (DMID), 
National Institute of Allergy and Infectious Diseases (NIAID) , 
National Institutes of Health (NIH ) 
 
 
Site Principal Investigator:  [INVESTIGATOR_236502] B. Smith , MD  
 
DMID  Clinical Project Manager:  Maureen Mehigan , RN 
 
Version  Number: 5.0 
 
10 July 2023 
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     2 STATEMENT OF COMPLIANCE  
The clinic al trial will be carried out in accordance with Good Clinical Practice (GCP) and as 
required by [CONTACT_716]: 
• [LOCATION_002] (U .S.) Code of Federal Regulations (CFR) applicable to clinical trials  
(45 CFR Part 46 , 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312). 
• International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for  Human Use E6(R2) Good Clinical Practice (ICH E6 GCP): Integrated 
Addendum to ICH E6(R1) Guidance for Industry, published in the Federal Register (83 Federal Register 8882 (2018)), including the latest finalized National Institutes of Health 
(NIH) Clinical Terms of Award, as applicable. 
Compliance with these standards provides public assurance that the rights, safety, and well -being 
of subjects are protected, consistent with principles that originate in the Declaration of Helsinki.  
All key personnel (all individuals responsible for the design and conduct of the trial) have completed Human Subjects Protection Training.  
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     3 SIGNATURE [CONTACT_469449] e trial will be conducted according to all stipulations of the protocol, 
including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable U.S. federal regulations and ICH guidelines. 
 
 
 Site Investigator:   
 William B. Smith, MD 
_________________________________________________ 
Name/Title (Print)  
 
 
Signature:  _________________________________________________ 
 
Date:   _________________________________________________ 
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601664] Risks ........................................................31 
 Venipuncture and IV Catheter Placement Risks  ...........................................32 
 Additional Risks............................................................................................32 
2.7 Known Potential Benefits .........................................................................................32 
2.8 Risk/Benefit Ratio  .....................................................................................................32 
3 Objectives and Outcome Measures .......................................................................................34 
3.1 Study Objectives .......................................................................................................34 
 Primary  ..........................................................................................................34 
 Secondary  ......................................................................................................34 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601665] to Follow-up ..........................................................................................44 
 Termination of Study ....................................................................................44 
6 Study Intervention/investigational product ...........................................................................[ADDRESS_601666] Storage and Stability........................................................................46 
6.2 Dosage, Preparation, and Administration of Study Intervention/ Investigational 
Products.....................................................................................................................46 
6.3 Modification of the Study Intervention/ Investigational Products ............................47 
 Overdose .......................................................................................................47 
6.4 Accountability Procedures for the Study Intervention/ Investigational Products .....[ADDRESS_601667] Compliance with the Study Intervention/ Investigational Products.....................................................................................................................48 
6.6 Prior and  Concomitant Medications/Treatments  .....................................................49 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601668] Restrictions  and Precautions .......................................................................50 
 Smoking ........................................................................................................50 
 Physical Activity  ...........................................................................................50 
 Food and Fluid intake ...................................................................................50 
 Alcohol, Marijuana and Illicit Drugs ............................................................50 
 Caffeinated beverages  ...................................................................................51 
 Exposure to loud noise ..................................................................................51 
7 Study Schedule .....................................................................................................................52 
7.1 Recruitment  ...............................................................................................................52 
7.2 Screening Visit (Day -28 to Day -3) .........................................................................52 
7.3 Check -in (Day  -2) .....................................................................................................53 
7.4 Baseline (Day  -1) ......................................................................................................54 
7.5 Inpatient Treatment Period (Days 1 to 3) .................................................................55 
 DAY 1: Administration of Study Drug – Bronchoscopy (Cohorts T1 – 
T4) .................................................................................................................55 
 DAY 2: Inpatient Follow -up – Bronchoscopy T5 ........................................57 
 DAY 3: Inpatient Follow -up .........................................................................58 
7.6 Outpatient Follow -up Period (Days 14 and 30) ........................................................59 
 DAY 14 (± 3 days) ........................................................................................59 
 Day 30 (± 4 days) – FINAL VISIT  ...............................................................59 
7.7 Early Termination (if needed) ...................................................................................60 
7.8 Unscheduled Visit (if needed) ..................................................................................60 
8 Study Procedures/evaluations ...............................................................................................62 
8.1 Clinical Procedures/Evaluations ...............................................................................62 
 Informed Consent..........................................................................................62 
 Demographics ...............................................................................................62 
 Inclusion/Exclusion Criteria .........................................................................62 
 Medical History  ............................................................................................62 
 Physical Examination ....................................................................................63 
 Vital Signs  .....................................................................................................63 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601669] Electrocardiogram (ECG)  .................................................64 
 Spi[INVESTIGATOR_038] .....................................................................................................64 
8.2 Laboratory Evaluations .............................................................................................64 
 Clinical Laboratory Evaluations (Hematology, Coagulation, Chemistry, 
and Urinalysis). .............................................................................................[ADDRESS_601670]  ............................................................................66 
 Urine Cotinine Testing  ..................................................................................66 
 Exploratory Biomarkers for Renal Injury .....................................................66 
 Serum Cystatin C  ..............................................................................66 
 Urinary KIM -1 ..................................................................................66 
8.3 Bronchoscopy with Bronchoalveolar Lavage ...........................................................66 
8.4 Ear Examination and Otoacoustic Testing ................................................................67 
8.5 Bioanalytical Assays for Pharmacokinetics (PK)  .....................................................[ADDRESS_601671] for Apramycin in Plasma ............................................68 
 Assays for Total Apramycin in Bronchoalveolar Lavage Components 
(ELF and AM) ...............................................................................................69 
 Plasma and BAL Urea assay  .........................................................................69 
 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007] ...........................................69 
 Instructions for Specimens Preparation, Handling, and Storage ......69 
 Specimen Shipment ..........................................................................69 
 Long- term Storage of Plasma and BAL (ELF and AM) PK Samples  ..........70 
9 Assessment of Safety  ............................................................................................................71 
9.1 Specification of Safety Parameters  ...........................................................................71 
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters 71 
 Adverse Events  .............................................................................................71 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601672] 
Values or Abnormal Clinical Findings .........................................................74 
9.3 Reporting Procedures ................................................................................................74 
 Serious Adverse Events ................................................................................74 
 Regulatory Reporting for Studies Conducted Under DMID-Sponsored 
IND ...............................................................................................................75 
 Other Adverse Events (if applicable) ............................................................76 
 Reporting of Overdose ......................................................................76 
 Reporting of Pregnancy ................................................................................76 
9.4 Type and Duration of Follow-up of Subjects after Adverse Events .........................77 
9.5 Halting Rules  ............................................................................................................77 
 Study Halting Criteria  ...................................................................................77 
9.6 Safety Oversight........................................................................................................78 
 Safety Monitoring Committee (SMC)  ..........................................................78 
10 Clinical Monitoring ...............................................................................................................79 
10.1 Site Monitoring Plan  .................................................................................................79 
11 Statistical Considerations  ......................................................................................................80 
11.1 Study Hypotheses......................................................................................................80 
11.2 Sample Size Considerations  ......................................................................................80 
11.3 Safety Review  ...........................................................................................................80 
11.4 Final Analysis Plan  ...................................................................................................80 
 Analysis Populations .....................................................................................81 
 Demographics and Baseline Characteristics  .................................................81 
 Safety Analysis  .............................................................................................81 
 Adverse and Serious Adverse Events ...............................................81 
 Additional Safety Analyses...............................................................82 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     9 
 PK Analysis  ..................................................................................................82 
 Plasma PK parameters:  .....................................................................82 
 Bronchoalveolar ELF and AM PK parameters:  ................................83 
 Ratio of exposure parameters of Lung PK to Plasma PK: ................83 
 Missing Values and Outliers .........................................................................83 
 Analysis of ECG Parameters  ........................................................................84 
 ECG Analysis and Interpretation ......................................................84 
 Categorical Analyses  ........................................................................84 
 Cardiac Abnormalities: .....................................................................85 
 Analysis of Audiology Data..........................................................................85 
 Interim Reports  .............................................................................................85 
12 Source Documents and Access to Source Data/Documents  .................................................86 
13 Quality Control and Quality Assurance ................................................................................87 
14 Ethics/Protection of Human Subjects ...................................................................................[ADDRESS_601673]  .......................................................................................88 
14.3 Informed Consent Process ........................................................................................88 
14.4 Exclusion of Women, Minorities, and Children (Special Populations) ....................[ADDRESS_601674] Keepi[INVESTIGATOR_007] .....................................................................................93 
15.1 Data Management Responsibilities ...........................................................................93 
15.2 Data Capture Methods  ..............................................................................................93 
15.3 Types of Data ............................................................................................................93 
15.4 Timing/Reports  .........................................................................................................94 
15.5 Study Records Retention...........................................................................................94 
15.6 Protocol Deviations ...................................................................................................94 
16 Publication Policy  .................................................................................................................95 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     10 17 Literature References  ............................................................................................................96 
18 Appendices............................................................................................................................99 
Appendix A: Schedule of Study Procedures and Evaluations .....................................................100 
Appendix B: Adverse Events Toxicity Grading Criteria .............................................................102 Appendix C: Blood Volume Withdrawn During the Trial ..........................................................[ADDRESS_601675] OF TABLES  
Table 1: Schedule of Events ....................................................................................................... 100 
Table 2: Toxicity Grading Tables – CLINICAL AEs  ................................................................ 103 
Table 3: Toxicity Grading Tables – LABORATORY AEs  ........................................................ 107 
Table 4: Toxicity Grading Tables – ECG  ................................................................................... 110 
Table 5: Laboratory Samples and Estimated Total Blood Volume (mL) ................................... [ADDRESS_601676] OF FIGURES  
Figure 1: Description Schematic of Study Design ........................................................................ 22  
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601677] OF ABBREVIATIONS  
AAC(2) -Ia Acetyltransferase (2) subtype Ia  
AAC(3)- IV Acetyltransferase (3) subtype IV  
ACE  Angiotensin-Converting Enzyme 
AE Adverse Event  
AII Angiotensin II 
ALT  Alanine Aminotransferase 
AM Alveolar Macrophages  
AMR  Alliance for Multispecialty Research  
ARA Angiotensin II- receptor antagonists  
APTT Alpha Partial Thromboplastin Time  
AP Alkaline Phosphatase 
AST  Aspartate A minotransferase  
AUC  Area Under the Concentration – Time Curve 
AUC (0-t) Area under the concentration time- curve from time zero to time t  
AUC (0-24) Area under the concentration time- curve from time zero to 24 h 
AUC (0-∞) Area under the concentration time -curve from time zero to infinity  
AUC (0-last) Area under the concentration time- curve from time zero to the last 
concentration above the lower limit of quantitation 
β-HCG Beta Human Chorionic Gonadotropin 
BAL  Bronchoalveolar Lavage  
BMI  Body Mass Index 
BP Blood Pressure 
bpm Beats per Minute  
BUN Blood Urea Nitrogen 
CBC  Complete Blood Count 
CDC  Centers for Disease Control and Prevention 
CKD – EPI  [INVESTIGATOR_469337] 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     12 CL T Total Clearance  
CMS  Clinical Materials Services  
ConMed(s) Concomitant Medication(s)  
COAG Coagulation 
COX-[ADDRESS_601678]-in Human 
FH Family History  
fT3 Free triiodothyronine (T3)  
fT4 Free thyroxine ( T4) 
FVC  Forced Vital Capacity  
ELF Epi[INVESTIGATOR_469338] -Stimulating Hormone  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     13 FWA  Federalwide Assurance  
g Gram(s)  
GCP  Good Clinical Practice  
GFR  Glomerular Filtration Rate  
eGFR  Estimated GFR  
h Hour(s)  
HAP  Hospi[INVESTIGATOR_469339] B Surface Antigen  
Hct Hematocrit  
HCV Hepatitis C Virus  
HEENT  Head, Eyes, Ears, Nose, and Throat 
HEM  Hematology Panel  
Hgb Hemoglobin 
HIPAA  Health Insurance Portability and Accountability Act 
HIV Human Immunodeficiency Virus 
HPF High -Powered Field  
HIPAA  Health Insurance Portability and Accountability Act 
HLGT  High Level Group Term 
HR Heart Rate  
IATA  International Air Transport Association  
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Council for Harmonization  
ICMJE  International Committee of Medical Journal Editors  
IM Intramuscular  
IMP Investigational Medical Product 
IND Investigational New Drug  
INR International Normalized Ratio  
IRB Institutional Review Board  
IUD Intrauterine Devise  
IV Intravenous 
kg Kilogram(s)  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     14 KIM  Kidney Injury Molecule  
LC-MS/MS  Liquid Chromatography with Tandem Mass Spectrometry 
LLN  Lower Limit of Normal  
LQTS  Long QT Syndrome 
MBC  Minimal Bactericidal Concentration  
MDMA  3,4-methylenedioxy- methamphetamine  
MDR  Multiple Drug Resistant 
MedDRA Medical Dictionary for Regulatory Activities  
MRSA  Methicillin Resistant Staphylococcus aureus  
MM Medical Monitor 
µg Microgram(s)  
mg Milligram(s)  
MH Medical History  
MI Myocardial Infarction  
MBC  Minimal Bactericidal Concentration  
MIC  Minimal Inhibitory Concentration 
min Minute(s) 
mL Milliliter(s)  
MM Medical Monitor 
mmHg  Millimeters of Mercury  
mmol Millimole(s)  
MOP  Manual of Procedures 
msec Milliseconds(s)  
N Number (typi[INVESTIGATOR_469340]) 
n Number (typi[INVESTIGATOR_306037] a subset of the total number of subjects) 
NIAID  National Institute of Allergy and Infectious Diseases , NIH  
NIH National Institutes of Health  
NOAEL  No Observable Adverse Effect Level  
NSAID  Nonsteroidal Anti -Inflammatory Drug 
OAEs  Otoacoustic emissions  
OER  Office of Extramural Research, NIH  
OTC  Over  the Counter 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601679]-bronchoscopy Fever 
PD Pharmacodynamic(s) 
PE Physical Examination  
PI [INVESTIGATOR_12453](s)  
POC  Point of Contact 
[CONTACT_469376]’s Formula 
RAAS Renin  – Angiotensin - Aldosterone System  
RNA Ribonucleic Acid  
rRNA  ribosomal ribo nucleic acid  
RBC  Red Blood Cell 
RP Research Pharmacist  
RR Respi[INVESTIGATOR_469341](s) 
SMC  Safety Monitoring Committee  
SNHL  Sensorineural Hearing Loss 
SOC  System Organ Class  
SSP Study Specific Procedures 
STH6  Score Threshold 
T Temperature  
TCA  Tricyclic Antidepressant 
Tmax Time to Maximum Concentration  
TEAE Treatment -emergent Adverse Event  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601680]  Upper Limit of Normal  
US [LOCATION_002]  
UTMC  University of Tennessee Medical Center, Knoxville 
t1/2 Terminal Elimination Half -life 
TLF Tables, Listing and Figures 
TN Tennessee  
VAP  Ventilator -associated Pneumonia 
Vd Volume of Distribution  
VS Vital Signs  
Vz/F Apparent volume of distribution 
WBC  White Blood Cell 
WHO  World Health Organization 
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     17 PROTOCOL SUMMARY  
Title:  A Phase I, O pen-Label Study to Assess Lung 
Pharmacokinetics and Safety of a Single Dose of 
Apramycin Administered Intravenously in Healthy Adult Subjects. 
Phase:  1 
Population: Approximately 20 evaluable healthy male or female 
subjects 18 to 45 years of age (both inclusive) at the 
time of dosing. 
Number of Sites:  One (Alliance for Multispecialty Research [ AMR ] 
Phase 1 clinical trial unit [ CTU ], Knoxville, 
Tennessee [TN] [(AMR -Knoxville]). 
Study Duration:  Approximately [ADDRESS_601681] Participation Duration: Up to 58 days (from Screening Visit to F inal V isit). 
The trial will consist of  a Screening Period of up to 
26 days as outpatient ( Day -28 to Day  -3); a Check -
in Day (Day -2); Baseline Day (Day  -1); a 
Treatment  Period of 3 days (Days 1 to 3) as 
inpatient, with dosing on Day 1 and follow-up on Days 2 and 3; and a n out- patient  Follow-up P eriod  
of 27 days (Days 4 to 30) with two site visits, on 
Day 14 (± 3 day s) and Day  30 (± 4 days) (Final 
Visit) . 
Description of Agents:  Apramycin is a mono- substituted 2 -
deoxystreptamine compound that represent s a 
subclass of aminoglycoside antibiotics. Apramycin 
is provided in 20 mL vials as an aqueous solution of 
150 mg/mL apramycin base, with pH adjusted to 
5.5 to  6.0 with sulfuric acid . The filling volume is 
19 mL,  and the extractable volume is 18 mL. A 
singl e dose of 30 mg/kg will be administered 
intravenously (IV)  in a total volume of 30 mL over 
a period of 30 (± 5) min as an open label . Sterile 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601682] ( IMP) 
concentration.  
Objectives:  Primary:  
• To assess plasma pharmacokinetic (PK) 
profile of apramycin and lung penetration of 
apramycin in epi[INVESTIGATOR_71444] (ELF) and alveolar macrophages (AM) after single intravenous (IV) apramycin dose of 30 mg/kg in healthy subjects .  
Secondary:  
• To assess the safety of single IV administration of 30 mg/kg apramycin in healthy subjects. 
• To assess changes in otoacoustic testing .
  
Exploratory:  
• To assess changes in kidney function biomarkers. 
Outcome Measures:  Primary:  
• Lung concentration and PK parameters  of total 
apramycin : 
o ELF: C max, AUC (0-24), AUC (0-t), AUC (0-∞), Tmax, 
t½ 
o AM: C max, AUC (0-24), AUC (0-t), AUC (0-∞), Tmax, 
t½ 
• Plasma  concentration and PK parameters  of total 
apramycin :  
o AUC (0-∞), AUC (0-t), AUC (0-24), Cmax, Tmax, t½, 
CL T, V d central  
• Ratio of exposure parameters of Lung PK to 
Plasma PK:  
o ratio of C max in ELF over C max in plasma  
o ratio of C max in AM over C max in plasma  
o ratio of AUC (0-24), AUC (0-t), and AUC (0-∞) in 
ELF over AUC (0-24), AUC (0-t), and AUC (0-∞) in 
plasma  
o ratio of AUC (0-24), AUC (0-t), and AUC (0-∞) in 
AM over AUC (0-24), AUC (0-t), and AUC (0-∞) in 
plasma  
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     19 Secondary:  
• Type and incidence of treatment -emergent 
adverse events (TEAE s) and serious adverse 
events (SAEs) to  Day  30 (± 4 days) after dosing . 
• Frequency of clinically significant TEAEs in 
physical examination (PE) findings or changes 
from baseline in vital signs  (VS)  and cl inical 
laboratory parameters to Day 14 (± 3 days) after 
dosing. 
• Frequency of changes in electrocardiographic 
(ECG ) intervals (QTcF, PR, QR S, HR ) and 
morphology from baseline until 24 h ± 1 h after 
dosing. 
• Type and incidence of TEAEs related to 
auditory (cochlear) function tests ( pure-tone 
audiometry and distortion product otoacoustic 
emissions [ DPOAEs ]) to Day 30 ( ± 4 days) after 
dosing.  
Exploratory:  
• Changes from baseline in urinary kidney injury 
molecule 1 (KIM-1) and serum cystatin C  
concentrations until Day 30 (± 4 days ) after 
dosing. 
Description of Study Design:  Open label study of a single dose of 30 mg/kg of 
apramycin administered intravenously (IV) over 30 
(± 5) min utes. Twenty s ubjects will be enroll ed in 
the study to one of 5 cohorts , T1-T5, each 
corresponding to a timepoint after initiation of infusion at which a single fiberoptic bronchoscopy 
with bronchoalveolar lavage (BAL) is performed . 
There will be [ADDRESS_601683] 2 hour s apart.  
Bronchoscopy with BAL will be performed under 
sedation or light an esthesia and oxygenation 
support. Apramycin concentrations after IV 
infusion will be measured in BAL and alveolar 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     20 macrophages (AM) prepared by [CONTACT_469377] . Apramycin concentrations in 
epi[INVESTIGATOR_71444] (ELF)  will be corrected for 
dilution using the urea method. BAL samples will 
be collected at the following timepoints a fter the 
start of the infusion in each T cohort : 30 min ± 
5 min  (T1), 2 h ± 5 min  (T2), 4 h ± 10 min (T3), 8 h 
± 15 min (T4) or 24 h ± 1 h (T5). The timing of T5 is nominal; final time will be determined after 
analysis of apramycin concentrations in the BAL 
(ELF and AM) in  cohorts T1 -T4. 
Apramycin concentrations (total) will be measured 
in plasma samples prepared from blood samples 
collected pre- dose, and at the following timepoints 
after the start of the infusion: 30 ± 5 min , 1 h ± 
5 min , 2 h ± 5 min , 4 h ± 10 min, 8 h ± 15 min , 16 h 
± 15 min , 24 h ± 1 h, 36 h ± 1h, 48 h ± 1 h and 60 h 
± 1 h after dosing. An additional plasma PK sample may be collected at the end of the BAL sample collections if bronchoscopy with BAL is delayed. 
Free apramycin concentration will be measured at 
30 ± 5 min (immediately after the end of infusion) and at 36 h ± 1h.   
Urea concentration will be measured in plasma  and 
time-matched BAL  samples as a volume dilution 
marker  of BAL ELF . 
All concentration measurements for apramycin and 
urea will be performed with validated bioanalytical 
assays.  
Safety will be evaluated by [CONTACT_469378], VS measurements, safety  clinical 
laboratory tests, and  
12-lead standard ECGs . Potential nephrotoxicity 
will be evaluated with creatinine concentrations and 
estimated glomerular  filtration rate (eGFR) and 
exploratory biomarkers in plasma (Cystatin C) and 
urine (kidney injury marker 1 [ KIM -1]). Potential 
ototoxic effects will be evaluated by [CONTACT_469379] (audiometry and DPOAEs ). 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     21 Changes in assessments after administration of the 
IMP and comparison with the pre-dosing baseline will be reported. TEAEs and SAEs will be collected 
and graded from the time of dosing to completion of the study (Day 30 ± 4 days ). A Safety 
Monitoring Committee (SMC) will oversee the conduct of the study. 
Estimated Time to Complete 
Enrollment  Up to 6 months (from dosing of first subject to Final Visit of last subject ). 
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     22 Figure 1: Description Schematic of Study Design   
NOTE: All subjects who signed the ICF and met screening criteria will have baseline 
assessments on Day -2 and Day - 1. Following a single IV dose of 30 mg/kg of apramycin, blood 
will be drawn for measuring the concentration and PK parameters of total plasma apramycin starting on Day 1 and finishing on Day 3 at the indicated timepoints. A single bronchoscopy with bronchoalveolar lava ge will be performed after initiation of dosing at one of the following 
timepoints in the respective cohorts: 30 min (T1), 2 h (T2), 4 h (T3), 8 h (T4), and 24 h (T5). Total apramycin concentration will be measured at each BAL timepoint and PK parameters will 
be estimated in BAL fluid  (containing ELF) and BAL AM . Four subjects will be assigned to 
each T cohort. Enrollment and dosing will be rolling and coordinated with the bronchoscopy service. For each cohort, if [ADDRESS_601684] visit on Day 30, and will include physical examination, vital signs, ECG, clinical laboratory tests (hematology, chemistry and urinalysis), audiology examinations (ENT exam, audiometry, DPOAE s), and exploratory 
markers of nephrotoxicity (serum cystatin C and urinary KIM-1).   
 
 
 

DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     23 1 KEY ROLES  
Site Principal Investigator: [INVESTIGATOR_236502] B. Smith, MD  
AMR -Knoxville  
[ADDRESS_601685] 
Knoxville, TN [ZIP_CODE] Office:  [PHONE_9811] ext.246   
Email: [EMAIL_8997]  
 
Site Pneumono logist : John C. Callison, Jr., MD  
University of Tennessee Medical Center  
c/o AMR -Knoxville  
[ADDRESS_601686] Knoxville, TN [ZIP_CODE] Office: [PHONE_9812] 
Email: [EMAIL_8998]   
 
DMID Clinical Project Manager:  Maureen Mehigan , RN 
DMID/ NIAID /NIH/HHS  
[ADDRESS_601687], Room 7E19   
Bethesda, MD  [ZIP_CODE] 
Office : [PHONE_9813] 
Email: [EMAIL_1390]   
  
Statistical and Data Coordinating Center (SDCC) : 
The Emmes Company , LLC  
[ADDRESS_601688] 
Rockville, MD [ZIP_CODE] 
Phone: [PHONE_2269] Fax: [PHONE_9814] 
Email: [EMAIL_8999]    
 
Bioanalytical Laboratory: KCAS Bioanalytical and Biomarker Services  
[ADDRESS_601689] 
Phone: [PHONE_9815] 
Fax: 913-248_3106 
Email: [EMAIL_9000]   
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601690] defended a strong clinical presence ever 
since and until today. 
The common mode of action of aminoglycoside antibiotics is the disruption of bacterial protein 
synthesis by [CONTACT_53167] 16S ribosomal nucleic acid (rRNA) of the decoding site inside the 
small ribosomal subunit. Aminoglycosides are chara cterized by [CONTACT_469380]-
dependent killing and demonstrate significant post- antibiotic effect (PAE). All aminoglycosides 
including apramycin are polar, poly- cationic, and highly water -soluble, a property that limits 
their ability to cross lipid -rich cellular membranes of the host cells.  
Mainly due to the common recognition of the rapid bactericidal activity of aminoglycosides - 
also at very high bacterial burden - the drug class has established itself as an important therapeutic component in the treatment of serious hospi[INVESTIGATOR_469342]. Despi[INVESTIGATOR_469343], 
aminoglycosides still remain an extremely important therapeutic option.  The World Health 
Organization (WHO) continues to classify aminoglycoside antibiotics as Essential Medicines 
(WHO 20 19a) and as Critically Important Antimicrobials for Human Medicine (WHO 2019b). 
The therapeutic efficacy of standard -of-care aminoglycosides currently in clini cal use is 
compromised by [CONTACT_469381]. Infections with antibiotic -resistant bacteria caused an estimated 33,000 deaths in Europe 
in 2015 (Cassini 2018). According to the CDC’s Antibiotic Resistance Threats in the United 
States, 2019, more than 2.8 million antibiotic -resistant infections occur in the U.S. each year, and 
more than 35,000 people die as a result (CDC 2019). Bacterial pathogens highly resistant to various classes of antibiotics are estimated to account for a total of about 700,000 deaths 
annually worldwide. Without successful intervention, the burden of continued emergence and 
global spread of antimicrobial resistance is expected to multiply by [CONTACT_2892] 2050 (O’Neil 2014; CDC 2019).  New antibiotics are needed to adequately respond to the increasing prevalence of 
drug- resistant infections . 
2.[ADDRESS_601691] -of-care 
aminoglycoside antibiotics (gentamicin, amikacin, tobramycin, arbekacin, plazomicin and others) and, therefore, represents a subclass of aminoglycosides (O’Connor 1976). 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     25 Apramycin was originally approved as an oral and intramuscular veterinary antibiotic in the 
European Union (EU) for various indications (e.g., colibacillosis and salmonellosis in calves, 
bacterial enteritis in pi[INVESTIGATOR_14107], or Escherichia coli  septicemia in poultry  (EMA 1999). Its use as a 
growth-promot er in livestock has been banned in the 1980’s and it is authorized only for clinical 
veterinary targeted therapy in the EU and the [LOCATION_003] (EU Commission 2005, FDA 2021).  
Antibacterial activity  
Apramycin is active against a wide variety of pathogenic Gram -positive and Gram- negative 
bacteria including pathogens with resistance to gentamicin and all other clinical aminoglycosides 
of relevance. The primary therapeutic spectrum comprises all relevant Enterobacterales  
including Escherichia coli, Klebsiella spp., Enterobacter spp., Serratia marcescens, Morganella morganii, Citrobacter freundii, and Providencia spp (Smith 2016, Juhas 2019) . The activity 
against Providencia spp. is  of note because of its chromosomal aac ( 2’)-Ia gene that causes 
intrinsic resistance to several aminoglycoside antibiotics including plazomicin, the newest 
semisynthetic aminoglycoside to receive Food and Drug Administration (FDA) market approval. 
Apramycin also has significant in vitro activity against multi-drug resistant Acinetobacter baumannii  and Pseudomonas aeruginosa (Kang 2017, Juhas 2019). Amongst Gram -positive 
cocci, both methicillin -sensitive and resistant Staphylococcus aureus  (MRSA) are sensit ive to 
apramycin  (Truelson 2018). The in vitro  minimum inhibitory concentration (MIC) of apramycin 
against drug- susceptible clinical isolates at neutral pH tends to be about 4-fold lower than that of 
gentamicin, and about 2-fold lower than that of amikacin. The potency of apramycin at slightly 
acidic pH is similar to that of gentamicin and amikacin. The overall MIC90 of apramycin is 
8 μg/mL against highly drug- and carbapenem -resistant Enterobacterales (IB 2021, Juhas 2019).  
Apramycin treatment in mouse models of urinary tract infection ( UTI), septicemia, pneumonia, 
and neutropenic thigh infection significantly reduced the bacterial burden even with bacterial 
isolates that are multidrug -, carbapenem - and plazomicin- resistant  (Becker 2020 , IB 2021).  
Safety Pharmacology   
In vitro  and ex vivo  studies showed no relevant secondary pharmacological effects on receptors 
or ion channels, which indicates that no off- target effects of apramycin are to be expected. The 
rat calcium channel  N-type appeared to show full inhibition at 2 mM. This receptor interaction 
has been reported to be associated with the reversible neuromuscular blockade that can be 
commonly induced by [CONTACT_469382]. In vitro  investigation of effects on 
human ether-a-go-go-related gene (hERG) potassium channel assays in Chinese hamster ovary (CHO) cell lines showed IC
50 > 40 mM. High IC 50’s were also found for patch recordings of the 
Nav 1.5 sodium channel (>3 mM) in CHO cells and the Cav 1.2 channel in CHO cells (between 
1 to 3 mM), suggesting no potentially clinically significant effects (IB  2021). 
Nonclinical Assessment of Safety  
Extensive nonclinical safety core battery studies have been conducted in the rat and the Beagle 
dog to evaluate the effects of apramycin on organ systems  (IB 2021). 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     26 Repeat -dose toxicity studies identified the kidneys as the main target organ of toxicity. 
Nephrotoxicity manifested as increases in plasma creatinine and BUN, and histopathological changes in the kidney, primarily tubular necrosis with or without regeneration . Nephrotoxicity 
was exposure- related, with a lower incidence and severity after the recovery period,  suggesting 
potential reversibility. Nephrotoxicity appeared to correlate better with cumulative exposure than 
with total AUC
 (0-24) (IB 2021).  
Ototoxicity is a known risk of aminoglycosides. A repeat , 16-day dose study in guinea pi[INVESTIGATOR_469344], and cochlear function was partly retained even at high concentrations (430 mg apramycin/kg 
body weight). “No ototoxic effects were observed in the guinea pig model at the 152 mg/kg/day 
dose level.  This would convert to a human equivalent dose (HED) of 33.3 mg/kg, a single dose 
exposure of 0.8 mMÅ~h, and a cumulated exposure of 13.7 mMÅ~h, all of which are markedly higher than the nephrotoxic no observed adverse effect levels (NOAELs) in both rats and dogs.” 
(Matt 2012) Recent literature data support the finding that apramycin is of lower ototoxicity than 
gentamicin (Ishikawa 2019).  
Besides nephrotoxicity and ototoxicity, no other noteworthy findings in clinical signs and 
symptoms were observed. Apramycin showed no effects on the CNS, cardiovascular, or 
respi[INVESTIGATOR_27441] (IB 2021).  
No secondary pharmacological effects were observed. No mutagenic and no genotoxic effect s 
were observed. Therefore, no adverse effects or risks related to CNS, cardiovascular system, 
respi[INVESTIGATOR_469345]-target effects are to be expected. No special precautions regarding exposure to 
ultraviolet light have to be taken, as apramycin has no phototoxic potential. No signs of hepatotoxicity were observed in nonclinical safety pharmacology or toxicology studies. No fertility studies or data on embryofetal toxicity of apramycin are available to date. From 
veterinary toxicology data, no adverse effects on reproductive performance or evidence of 
maternal toxicity, fetal toxicity, or teratogenicity have been reported. Overall, the results of the nonclinical safety studies and toxicology studies are in line with the safety profiles reported for 
other aminoglycosides, e.g., gentamicin, amikacin and plazomicin (IB 2021). 
 Nonclinical Pharmacokinetics  
Pharmacokinetic (PK) data for apramycin is available for mouse, rat, guinea pig and dog. In 
animal models, the PK of apramycin was equivalent to benchmark aminoglycosides tested (e.g., 
gentamicin). Aminoglycosides are minimally absorbed in the gastrointestinal tract and thus must be administered intravenously (IV), subcutaneously (SC), or intramuscularly (IM) in order to 
treat systemic infections. Based on the volume of distribution, apramycin showed no wide tissue 
distribution. Protein binding was low, with fractions unbound (fu) of 90% in human and animal  
plasma. Apramycin was not metabolized. No interactions with cytochrome P450 (CYP) isoenzymes were found. Almos t all of the administered apramycin was excreted via the kidneys 
and recovered in urine. In mouse models, apramycin content in kidneys increased with 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     27 increasing doses and duration of treatment. At higher doses and with longer duration of 
treatment, apramycin exposure increased due to a decrease in renal excretion  (IB 2021). 
2.[ADDRESS_601692] adiose 
moiety. It represents a subclass of ami noglycoside antibiotics significantly different from the 
clinically well-established di-substituted 2-deoxstreptamines gentamicin, amikacin, tobramycin, 
arbekacin, plazomicin and others (Mingeot- Leclercq  1999). 
Based on its chemical structure, it was predicted that apramycin evades known aminoglycoside 
resistance mechanisms (Böttger & Vasella  2012). This was further confirmed by [CONTACT_15249] a 
panel of engineered E. coli  strains expressing isolated aminoglycoside resistance genes under 
equipotent constitutive promoter control, which showed the evasion of almost all known aminoglycoside-modifying enzymes involved in resistance (aminoglycoside acetyltransferases, phosphotransferases, and nucleotidyltransferases). The only exception is the acetyltransferase ( 3) 
subtype IV ( AAC (3)-IV) - a resistance gene that was previously described to confer apramycin 
resistance in animals  but is of low clinical prevalence when compared to all other 
aminoglycoside resistance mechanisms (Plattner  2020). Apramycin further retai ns binding to 
target sites methylated by [CONTACT_160153] (RNA) methyltransferases. In summary, cross-
resistance to clinically approved antibiotics has been demonstrated to be minimal (Böttger 2020). 
The antibacterial potency of apramycin against wild -type and drug resistant clinical isolates, has 
been endorsed by [CONTACT_469383] . An extensive data 
set on antibacterial potency of apramycin based on more than 1,[ADDRESS_601693]  (Juhas 2019) The MIC distribution and in vivo  efficacy 
of EBL -[ADDRESS_601694] highly drug- resistant A. baumannii  isolates and lung infections in mice has 
been particularly encouraging (Becker 2020). 
The aim o f the clinical development program for apramycin is to allow a full assessment of 
safety and efficacy as well as ensuring that the product is rapi[INVESTIGATOR_469346]-drug resistant ( MDR ) bacteria.  
2.[ADDRESS_601695]-in-Human (FIH) single dose escalation trial, single doses of 0.3, 1.2, 3.6, 10.8 and 
30 mg/kg apramycin were investigated in healthy volunteers. The subjects were randomized to either apramycin (6 per dose level) or placebo (2 per dose level). 
Safety  
Overall, single IV doses of EBL-1003 (apramycin) up to 30 mg/kg were safe and well tolerated 
in healthy subjects in this clinical trial. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     28 There were no deaths or discontinuations due to TEAEs during the study. The 2 SAEs observed 
during the study (1 in Dose Group 0.3 mg/kg: emotional disorder of moderate intensity; 1 in 
Dose Group 30 mg/kg: ligament rupture of moderate intensity) were both not related to the IMP. 
Overall, incidence of TEAEs w as low; with 9 subjects (22.5%) reporting altogether 13 TEAEs, 
mostly not (9 TEAEs), or unlikely (3 TEAEs) related to the IMP. Only for 1 TEAE (mild back 
pain in Dose Group 30 mg/kg), a causal relationship to the IMP was considered possible. The 
events wer e mainly mild (10 TEAEs) or moderate (3 TEAEs); no TEAEs of severe intensity 
were observed. Except for 1 TEAE for which outcome could not be ascertained (SAE: torn 
ligament) as the subject was lost to follow -up, all TEAEs were recovered or resolved at the end 
of the study. 
One subject in Dose Step [ADDRESS_601696] (pure tone audiometry with 
sensorineural hearing loss [SNHL] >3 dB). The SNHL was not confirmed upon re- measurement 
and therefore, this TEAE/AESI was assessed as unlikely related t o the study drug. 
No effects on safety laboratory parameters, vital signs, ECG parameters or exploratory biomarkers of renal toxicity were observed. No medically relevant effects were seen in otological examinations. 
EBL- 1003 (apramycin) was well tolerated  locally at the infusion site . 
There were 2 serious adverse events (SAEs):  
• One subject (0.3 mg/kg apramycin) had admitted himself to hospi[INVESTIGATOR_469347] [ADDRESS_601697] completed the 
entire course of the study up to the Day 90 visit. 
• One subject (30 mg/kg apramycin) was admitted to hospi[INVESTIGATOR_469348]. The event was not related to the study treatment (the subject had played soccer). He had completed the study up to Day 14. The subject was lost to follow-up, so the outcome and end date of the SAE could not be verified. 
Pharmacokinetics  
In the 30 subjects who received apram ycin, the plasma concentration profiles of apramycin were 
similar to those observed by [CONTACT_469384], such as gentamicin, after IV infusion. 
Exposure characteristics (AUC (0-t) and C max) increased with increasing doses with mean values 
(arithmetic a nd geometric) increasing by [CONTACT_469385]. 
Variability of AUC was small, with coefficients of variation <20%. Variability of C max was 
slightly larger . Observed mean exposure characteristics were in line with the predictions based 
on the population PK model for gentamicin (Xuan 2004) and the observed kidney function in the healthy volunteers. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     29 2.5 Rationale   
 Study Rationale 
In a study of apramycin in a mouse lung infection model demonstrated ≥ 90% lung penetration 
and multilog CFU reduction at doses of ≥ 5 mg/kg for an XDR Acinetobacter baumannii   
(A baumannii)  isolate with an MIC of 8 mg/L (Becker 2020). This finding warrants particular 
interest in determining the ability of apramycin to penetrate human lung tissue. It has previously 
been shown that the lung penetration of plazomicin or amikacin in mice is not a good indicator 
for the ELF targets in humans. Since apramycin has shown lung penetration in mice higher than 
that of plazomicin , it remains to be confirmed whether it also penetrates well into human ELF.  
The current Phase I lung pharmacokinetic study intends to administer apramycin in healthy subjects  by [CONTACT_469386]. It is the first 
step in assessing the pharmacokinetics of apramycin in the body compartments rele vant for 
diseases associated with bacterial respi[INVESTIGATOR_469349]- associated 
pneumonia/ventilator-associated pneumonia ( HAP/VAP ). Secondarily, this study will continue 
assessing the overall safety and tolerability of apramycin and exploring specifically ototoxic and nephrotoxic effect s. The effects on ECG will also be evaluated.  
 Rationale for Dose Selection 
A single dose of 30 mg/kg had been selected for this study based on the favorable safety and 
tolerability profile observed in the F IH clinical trial in healthy subjects (IB  2021). In addition, 
based on the translational PK -PD modeling study to assess efficacy, 30 mg/kg of EBL-1003 
(apramycin) is the anticipated therapeutic dose for future clinical investigations in patients  
(Tomas Sou 2021).  
2.6 Identified and Potential Risks and Benefits Associated with the Study  
 Risks and Benefits Associated with the S tudy Drug,  Apramycin  
Identified Risks  
There are no identified risks associated with apramycin  to date. Single apramycin  doses ranging 
from 0.3 to 30 mg/kg body weight were generally safe and well -tolerated in the FIH Phase 1 
clinical trial conducted in healthy subjects  (IB 2021).  
Potential Ri sks  
Based on the knowledge on other aminoglycosides, the following contraindications will be 
assumed for apramycin:  
• Known hypersensitivity to aminoglycosides  
• Myasthenia gravis  
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     30 Potential Drug  Interactions  
There are no clinical data on drug interactions with apramycin . 
Based on the knowledge on other aminoglycosides, concomitant administration of the following 
drugs should be avoided: 
• Drugs affecting renal function, e.g., renin–angiotensin aldosterone system [RAAS] 
inhibitors: angiotensin- converting enzyme [ACE]-inhibitors, angiotensin II [AII]- receptor 
antagonists, spi[INVESTIGATOR_8407], epleronone; non- steroidal anti-inflammatory drugs [NSAIDs] 
including cyclooxygenase 2 [COX- 2] selective inhibitors) . 
• Drugs with potential ototoxic effects, e.g., vancomycin, loop diuretics, quinine and quinidine derivatives including mefloquine. 
• Neuromuscular blocking agents. e.g., nondepolarizing (steroidal [ e.g., d-tubocurarine, 
rocuronium, vecuronium, pancuronium) and benzylisoquinolinium [e.g., mivacurium, 
atracu rium, cisatracurium]).  
• Other aminoglycosides, e.g., gentamicin, tobramycin, amikacin, plazomicin, streptomycin, neomycin, and paromomycin.  
 Use During Pregnancy and Lactation 
• Aminoglycosides pass the placenta barrier and may cause fetal harm. Therefore, apramycin should not be administered to pregnant women. 
• Aminoglycosides have been reported to be detected in maternal milk. Therefore, apramycin should not be administered to breastfeeding women. 
 Undesirable Effects  
Until clinical experience wi th apramycin is available, similar undesirable effects as observed for 
other aminoglycosides should be anticipated. Special attention should be paid to signs and 
symptoms of nephrotoxicity, ototoxicity, and vestibular toxicity. 
If symptoms are observed after the IMP has been administered, therapy has to be guided by [CONTACT_469387]. Subjects will have to remain under medical surveillance until all 
relevant symptoms have subsided. In case of adverse events, the investigator has to decide if the subject has to be withdrawn from the trial. Emergency drugs and equipment have to be available 
at the study site.  
 Overdose  
There is no specific antidote in case of apramycin overdose. The same measures as 
recommended for other aminoglycosides (treatment cessation, adequate hydration, dialysis, 
calcium salts ) should be considered until further clinical data are available for apramycin  
(IB 2021). 
 Drug Abuse and Dependency  
No clinical experience is available.  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601698] in both clinical 
applications as well as human research during more than 40 years of clinical use of this 
procedure in hundreds of thousands of subjects, without any serious lung troubles and si de 
effects. However, like all procedures, there are some risks associate with it  (Zhang 2020). 
The most common side effect related to the procedure is transient hypoxemia, which may require 
administration of oxygen, and transient tachycardia and premature contractions, which may 
require no treatment or appropriate intervention.   
Other side effects that could be related to the procedure include nausea and dizziness, due to the 
drugs used for sedation or anesthesia, and nasal stuffiness and irritation, throat irritation, 
hoarseness and cough, due to the passage of the bronchoscope and the bronchoalveolar  lavage 
(BAL).  
A post-bronchoscopy fever (PBF), typi[INVESTIGATOR_15120] 40°C / 100°F is rare and reported with 
variable rate, ranging from 0% to 10% in some series. It may occur approximately 8 h (range 4 to 
24 h) after BAL and lasts about [ADDRESS_601699] X-ray. Antibiotics are not used for prevention and treatment targets the symptoms (drugs to lower fever, good hydration). Additional tests may be needed to guide treatment  (Um 2004). 
Rare complications, with incidence 0.1 to 0.3%, are perforation of the bronchus with pneumothorax, atelectasis, and infection. Bleeding has been described for bronchoscopy with biopsy of the lung but is very rare (0.1% or less) if only BAL , and is related to me chanical 
trauma, especially in subjects who have a disorder of blood coagulation or take anticoagulants (heparin, warfarin, new anticoagulants) and non-prescription non- steroidal anti- inflammatory 
drug (such as aspi[INVESTIGATOR_248], and ibuprofen).  
These risks are mit igated by [CONTACT_469388] . During the 
bronchoscopy, subjects will be placed on supplemental oxygen and monitored continuously for 
oxygen saturation and ECG . Topi[INVESTIGATOR_412280], sedative or anesthetic dosages will be 
administe red according to standard medical practices by [CONTACT_469389][INVESTIGATOR_307]- certified staff. 
Pre- and post-bronchoscopy care will be provided and will include adequate nursing staff and 
standard post-sedation recovery care with direct investigator oversight. Finally, the procedure will be performed by [CONTACT_469390][INVESTIGATOR_307]- certified to perform this 
procedure and assisted by [CONTACT_469391][INVESTIGATOR_469350].  
 Audiometry and Otoacoustic test Risks  
Generally, there are no risks associated with the planned procedure s to examine the ear and 
assess cochle ar (hearing) function. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     32 
 Venipuncture and I V Catheter P lacement  Risks  
Venipuncture : Venipuncture causes transient discomfort and may cause fainting. Bruising at the 
site of venipuncture may occur but can be prevented or lessened by [CONTACT_92233]. Infection at the site is possible but highly unlikely as aseptic technique will be us ed. 
IV catheter placement : An indwelling catheter may be placed in an arm vein (preferabl y 
antecubital) for frequent blood drawing for PK measurements. The catheter may cause phlebitis 
with signs of redness and warmth at or near the IV insertion site, and thrombophlebitis with a hard area palpable near the IV insertion site. These risks are minimal as the IV catheters , when 
used, are only used briefly  after dosing. Careful inspection of the catheter site, including 
visualization of blood return, and withdraw al of the catheter if needed  will minimize this risk. 
There is a risk of infection; however, this is a small risk as aseptic technique will be us ed. 
 Additional Risks  
ECG:  Possible side effects from ECG patches include a rash or minor irritation of the skin. 
Blood draws:  The amount of blood drawn is about 25.7 mL  at Screening Visit , 22.2 mL on   
Day -2, 188.5 mL  during the inpatient period (Days 1 to 3), 22.2 mL at Day 14 Visit, 3.5 mL at 
Day 30 Visit, and 262.1 mL during the entire trial  (Appendix C, Table 5). Additionally, small 
amounts of blood loss may occur if an IV catheter is used or additional blood samples are collected (for repeat laboratory testing, TEAE  evaluation , etc.) . Overall, the amount of blood that 
may be drawn during the trial is within the amount that are considered safe to be drawn during short or extended period s, respectively, and not excessive for the safety and PK assessment 
requirements of Phase 1 trials . However, there is a small risk that some subjects may develop 
mild symptoms of hypovolemia or anemia during the trial. These are reversible with specific treatment s (e.g., fluid replacement, good nutrition, vitamins, or iron supplementation). 
2.[ADDRESS_601700] (HIPAA) regulation, 
subjects will be promptly notified of any clinical test results that would have an impact on their 
health. Screening evaluations may detect previously unknown abnormalities that could be clinically significant. This could benefit a subject , as it may lead to earlier diagnostic evaluation 
and treatment of an underlying disorder. 
2.8 Risk/Benefit Ratio  
This ratio cannot be calculated by [CONTACT_339583]. The risk for a n SAE  occurring in a subject 
treated with single doses of 30 mg/kg body weight is considered to be very low. Subjects will be 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     33 treated in an inpatient unit and closely monitored during the trial, so that appropriate emergency 
care can be provided immediately if an acute event occurs.  
Data collected in the clinical development of apramycin  to date, support further development of 
apramycin . The benefit of a potential new addition to the drugs available for the treatment of 
antibiotic -resistant bacteria and of using a new generation aminoglycoside with lower toxicity 
than licensed preparations, outweighs the known risks of the medication and the procedures to be 
used in this  trial.
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     34 3 OBJECTIVES AND OUTCOME MEASURES  
3.1 Study Objectives  
 Primary  
• To assess plasma pharmacokinetic (PK) profile of apramycin and lung penetration of 
apramycin in epi[INVESTIGATOR_71444] (ELF) and alveolar macrophages (AM) after single intravenous (IV) apramycin dose of 30 mg/kg in healthy subjects.  
 Secondary  
• To assess the safety of single IV administration of 30 mg/kg apramycin in healthy subjects . 
• To assess changes in otoacoustic testing .  
 Exploratory  
• To assess changes in kidney function biomarkers.  
3.2 Study Outcome Measures  
 Primary  
• Lung concentration o and PK parameters  of total apramycin : 
o ELF: C max, AUC (0-24), AU C(0-t), AUC (0-∞), Cmax, Tmax, t½ 
o AM: C max, AUC (0-24), AUC (0-t), AUC (0-∞), Cmax, Tmax, t½ 
• Plasma concentration and PK parameters  of total apramycin:  
o AUC (0-∞), AUC (0-t), AUC (0-24), Cmax, Tmax, t½, CL T, Vd central , 
• Ratio of exposure parameters of Lung PK to P lasma  PK: 
o ratio of C max in ELF over C max in plasma  
o ratio of C max in AM over C max in plasma  
o ratio of AUC  (0-24), AUC (0-t), and AUC  (0-∞) in ELF over AUC  (0-24), AUC (0-t), and  
AUC  (0-∞) in plasma  
o ratio of AUC  (0-24), AUC (0-t), and AUC  (0-∞) in AM over AUC  (0-24), AUC (0-t), and  
AUC  (0-∞) in plasma  
 Secondary  
• Type and incidence of treatment -emergent adverse events (TEAEs) and serious AEs 
(SAEs) to Day 30 ( ± 4 days) after dosing.  
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     35 • Frequency of clinically significant TEAEs in physical examination (PE) findings and of 
changes from baseline in vital signs  and clinical laboratory parameters  until Day 14  
(± 3 day s) after dosing.  
• Frequency of changes in ECG intervals (QTcF, PR, QRS, HR), and of morphological changes from baseline until 24  ± 1 h after dosing. 
• Type an d incidence of TEAEs related to auditory (cochlear) function tests (pure-tone 
audiometry and distortion product otoacoustic emissions [ DPOAEs ]) to Day 30 
(± 4 days) after dosing.  
 Exploratory 
• Changes from baseline in kidney injury molecule 1 (KIM-1) and serum cystatin C  
concentrations until Day  30 (± 4 days) after dosing . 
 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     36 4 STUDY DESIGN  
This is a Phase 1, single center, open -label, study to evaluate the plasma and lung 
pharmacokinetics (PK), safety and tolerability of a single intravenous (IV)  dose of apramycin  in 
twenty healthy male and female subjects  18 to 45 years of age (inclusive) .  
Each subject will be enrolled to one of five cohorts (T1-T5) before dosing on Day 1. Four 
subjects will be allocated to each cohort. Each cohort corresponds to the timepoint after dosing 
when a single bronchoscopy with bronchoalveolar lavage (BAL) will be performed : 0.5 h  
(± 5 min) (Cohort T1), 2 h (± 5 min) (Cohort T2), 4 h (± 10 min) (Cohort T3), 8 h (± 15 min) (Cohort T4), and 24 h (± 1 h) (Cohort T5). The timing of bronchoscopy and BAL in cohort T5  is 
nominal. The final time point will be determined after analysis of apramycin concentrations in 
BAL . If apramycin is detectable in BAL collected from cohorts T1- T4, then T5 will be enrolled . 
If it is  not detectable, then cohort T5 will not be enrolled. Blood will be collected at several 
timepoints to 60 hours after dosing (see collection schedule in Section 8.5.1) and will include 
samples that will coincide with BAL collections. The concentration and PK exposure parameters (C
max and AUC (0-t)) of total apramycin in epi[INVESTIGATOR_71444] (ELF) and alveolar macrophages 
(AM), collected through BAL, and in plasma collected at the sch eduled timepoints  to [ADDRESS_601701] four cohorts, T1-T4, to determine if apramycin penetrates into the lung tissues and dosing of the T5 cohort is warranted. If cohort T5 is dosed, the final 
concentration and PK analysis of apramycin in BAL samples and plasma will include data from 
all T1 -T5 cohorts. 
Subjects will participate in the study for approximately 58 days, including a 28-day screening 
period, consisting of an out-patient period of 26 days (Day -28 to Day -3) with 1 to 2 site visits 
and 2 inpatient days, D ay -2 and Day -1, to confirm eligibility, enroll and complete baseline 
assessments; a 3 -day in -patient treatment period, with treatment administered on Day 1, 
bronchoscopy with BAL done within 24 h after dosing, and in-patient follow up completed on 
Days 2 and 3; and a 27-day out- patient follow-up period with site visits on Day 14 (± 3 day s) and 
Day 30 ( ± 4 days) , the last follow up visit. It is anticipated that the duration of the study will be 
about [ADDRESS_601702] eligibility is determined. Enrollment and treatment  of subjects will be staggered and no more than two subjects will be dosed on a single 
day not less than 2 hours apart. Additional subjects may also be admitted to the Clinical Trial 
Unit (CTU) before dosing and may serve as back-up study subjects. A subject assigned to one of the T1 to T4 cohorts may be re assigned to another cohort depending on the availability of a 
bronchoscopy time slot. (See Section 5.3.1)   
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     37 Apramycin  will be reconstituted in sterile normal saline and a 30 mg/kg dose will be 
administered as a single IV infusion in a forearm vein over 30 min (± 5 min) using a syringe or 
infusion pump. (See Section 6.2 for DP preparation  and administration). 
Safety monitoring during the inpatient period will include: (a) S cheduled assessments per 
protocol: a physical examination (PE), vital signs (VS; including HR, BP, RR and T); 12- lead 
standard ECG (in triplicate at scheduled timepoints  on Day-1 matching planned t imepoints on 
Day 1 ); clinical safety laboratory tests ( Hematology [ HEM ], Coagulation [ COAG], Chemistry 
[CHEM ] including estimated Glomerular Filtration rate [eGFR] , and Urinalysis [ UA]; and 
audiology testing (middle ear examination  and cochlear testing [ hearing testing, consisting of 
pure-tone audiometry and DP OAEs ). Exploratory plasma and urinary nephrotoxicity biomarkers 
(plasma cystatin C and urinary KIM- 1) will also be measured . In addition, (b) Unscheduled 
assessments after bronchoscopy will be performed according to orders by [CONTACT_469392]. Subjects with on-going TEAEs will be followed until resolution or stability of the TEAE as assessed by [CONTACT_978]. 
Safety Monitoring Committee (S MC) Role 
A SMC  will be appointed to oversee the safe conduct of the trial, review safety data and provide 
recommendations on safety monitoring in the current and future clinical trials with apramycin . A 
scheduled interim SMC meeting will be held after all subjects in Cohorts T1- T4 complete all 
assessments. If the last cohort (T5) will be enrolled for dosing, a final SMC will be held to 
review cumulative data on all subjects . If Cohort T5 is not dosed, the interim meeting will be 
consider ed final.  
 If criteria for halt ing the trial (as listed in  Section 9.5.1) are met , enrollment and dosing of new 
subjects will be suspended, and an ad hoc  SMC meeting will be held to review all available 
safety data. Study procedures in subjects already enrolled and dosed will continue per schedule. 
A suspended clinical trial will resume upon recommendation by [CONTACT_469393], NIAID (the sponsor).  
4.1 Sub-studies  
No sub- studies are planned.  
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     38 5 STUDY ENROLLMENT AND WITHDRAWAL  
Only subjects who meet all inclusion criteria and no exclusion criteria will be eligible f or 
enrollment into th e trial. No exemptions are granted on Inclusion/Exclusion Criteria in DMID-
sponsored trials . 
Twenty  healthy male and female subjects , aged [ADDRESS_601703] to be eligible for study participation:  
1. Subject reads and signs the Informed Consent Form (ICF) and agree to have 
bronchoscopy with bronchoalveolar lavage under sedation or light anesthesia and comply 
with study procedures. 
2. Healthy male or non-pregnant, non- lactating female subjects  18 to 45 years of age (both 
inclusive) at the time of dosing .  
a. Note 1 : Determined by [CONTACT_9870] (MH), medication use, physical 
examination (PE), and vital signs , clinical laboratory tests and 12- lead ECG 
within reference ranges at Screening and Day -2. (See Sections 8.1 and 8.2,  
Appendix B , Table 2 , Table 3  and Table 4 and the study- specific MOP.)  
Exceptions to BP, HR and laboratory test values being with normal ranges are:  
o Abnormal HR and BP on first measurement may be repeated twice more with 
the subject resting between measurements for at least 5 min according to 
Section 8.1.6. 
o Subjects with baseline HR ≥ [ADDRESS_601704], AP, 
BUN, urine protein, serum creatinine or estimated glomerular filtration rate 
(eGFR) <70 mL/min /1.73 m
2 by [CONTACT_345276][INVESTIGATOR_51962] (CKD-EPI) equation. 
3. Female subjects of childbearing potential should use highly effective methods of 
contracepti on from the time of screening to 30 days after dosing. 
• Note  1: A female is considered of childbearing potential unless post-menopausal 
(defined as history of ≥1 year of spontaneous amenorrhea and a FSH level >40 IU/L), or permanently surgically sterilized.  
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     39 • Note 2 : Highly effective contraceptive methods include: (a) surgical sterilization 
methods, such as tubal ligation, bilateral oophorectomy, salpi[INVESTIGATOR_1656], 
hysterectomy, or successful tubal obliteration (e.g., Essure®) with documented 
radiological confirmation test at least 90 days after the procedure, or (b) long-acting reversible contraception, such as progestin-releasing subdermal implants, copper intrauterine devices (IUDs), levonorgestrel- releasing IUDs . 
• Note 3 : A subject who is not sexually active and abstains from sexual intercourse 
can be enrolled and abstinence documented.   
4. Males, including vasectomized men, having sexual intercourse with women of 
childbearing potential must agree to consistent use of condoms from IMP 
administration through at least [ADDRESS_601705] also agree to not donate 
sperm during this same time period. 
• Note : A subject who is not sexually active and abstains from sexual intercourse 
can be enrolled and abstinence documented. 
5. BMI 18.0 to  32.0 kg/m2 (inclusive) and body weight not less than 50 kg.  
6. Subjects with normal hearing, i.e., symmetric hearing with air conduction thresholds 
no worse than 20 dB hearing loss for the frequencies 0.5-1-2-4-6- 8 kHz bilaterally.  
7. Normal (reproducibility 70% or better) of distortion product otoacoustic emissions 
(DPOAEs ). 
Note : Absence of DPOAE s at no more than two consecutive or non-consecutive 
DPOAEs in each ear is acceptable. 
8. Normal otoscopic findings in the ears, normal tympanic membrane mobility and stapedial reflex present.  
9. From the signing of the informed consent until the last follow-up visit, subjects must 
be willing to avoid exposure to loud music or noise.  
• Note : Noise avoidance to include continuous usage of earpi[INVESTIGATOR_469351], 
attending loud concerts or dance events, or using firearms or attending fireworks. 
10. Normal lung function with Forced Expi[INVESTIGATOR_469352] (FEV1) 
predicted ≥ 80% and FEV1/Forced Vital Capacity (FVC) > 70%. 
11. Subjects must be willing to avoid excessive physical exercise within 48 h prior to dosing until discharge from the CTU on Day 3, and 24 h before each follow-up visit 
(Day 14 ± 3 days and Day 30 ± 4 days ). 
12. No history of acute febrile or infectious illness for at least [ADDRESS_601706] infection within 4 weeks prior to screening. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601707] to be eligible for study participation: 
1. Lactating females . 
Medical and surgical history:  
2. Any history of hypersensitivity to aminoglycosides. 
3. Any history of drug hypersensitivity, asthma, urticaria or other severe allergic diathesis.  
4. Any history of seasonal allergies with ongoing symptoms for more than a week prior to 
dosing requiring glucocorticoids and/or frequent use of antihistamines for treatment. 
5. Any history of a chronic condition that may increase risk to subject or interfere with 
endpoint assessment, or any unstable chronic disease.   
• Note  1: Unstable chronic disease is defined by [CONTACT_469394] f requent medical 
interventions that lead to a change in medications and/or required hospi[INVESTIGATOR_059], surgery or an invasive procedure or emergency department/urgent care visit. 
• Note 2 : Any chronic disease, that has been diagnosed within [ADDRESS_601708] is considered psychologically unstable by [CONTACT_093]. 
7. History of acute or chronic problems with hearing and/or balance in the last 24 months. 
• Note : These include but not limited to  use of hearing aid, head injury leading to 
otologic damage, tumor of the head or neck, autoimmune disease of the inner ear, 
tinnitus, vestibular disease, auditory neurinoma, endolymphatic hydrops and/or Meniere’s disease,  perilymphatic fistula, otitis media, laby[CONTACT_344105], sudden hearing 
loss, known retrocochlear hearing impairment, conductive hearing loss exceeding 10 
dB at any frequency, ear canal and/or middle ear disease including inflammation or 
effusion, pathological tympanometry. 
8. Past injury or surgery to the middle or inner ears.  
• Note : Myringotomy or tympanic tube insertion in childhood with complete healing 
and normal hearing test are excluded. 
9. Family history of hearing loss before the age of 60. 
10. Subjects who have had previous intolerance or contraindications to medications applied for sedation or anesthesi a during bronchoscopy. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     41 • Note : These include benzodiazepi[INVESTIGATOR_469353] (lidocaine or 
xylocaine) including reversal agents such as flumazenil .  
Laboratory examinations: 
11. Positive serum pregnancy test for women at screening or urine pregnancy test at c heck -in. 
12. Positive test for HIV antibodies, hepatitis B -virus surface antigen (HBsAg), or  
anti-hepatitis C -virus antibodies (anti- HCV).  
Prior medication:  
13.  Use of any prescription or non-prescription medication prior to the dose of IMP as 
described in Section  6.6. 
• Note : Exceptions are hormonal contraceptives, which are permitted throughout the 
study, and solitary doses of up to 1,[ADDRESS_601709] within 30 days or 5 half-lives (whichever is longer) 
before dosing.  
15. Planned participation in a clinical research study that requires treatment with a study drug or blood draws or other invasive assessments during the study period (screening until final 
visit). 
Lifestyle restrictions:  
16. More than low- risk alcohol consumption (men: ≥  24 g of pure alcohol regularly per day; 
women: ≥12 g of pure alcohol regularly per day)  for the previous [ADDRESS_601710] . 
18. Suspi[INVESTIGATOR_34906] / abuse or positive urine drug screen test (See Section 6.7.4 and 
Section  8.2.5 for prohibited substances). 
19. “History of ≥10 pack -years smoking, or history of any nicotine use in the 6 months before 
check -in (Day -2) or positive urine cotinine screen at check -in. 
• Note 1 : Nicotine products include cigarettes, e- cigarettes, pi[INVESTIGATOR_5836], cigar, chewing 
tobacco, nicotine patch. 
• Note 2 : A positive urine cotinine at screening is allowed if negative at check-in 
(Day  -2).  
20. Caffeinated beverages /foods are prohibited within [ADDRESS_601711] occupational noise exposure of high risk during the trial 
(e.g., construction site workers, military workers, etc.). 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     42 22. Blood or plasma donation of 500 mL within 3 months or more than 100 mL within 30 days 
before signing informed consent or planned donation prior to completion of this trial.  
5.3 Treatment Assignment Procedures  
 Enrollment Procedures  
Twenty  healthy subjects who consent to participate in the trial and mee t the eligibility criteria 
will be enrolled following admittance to the CTU  and confirmation of eligibility. Subjects will 
be registered using Advantage eClinical®, a web -based application developed by [CONTACT_469395], LLC, the DMID Statistical and D ata Coordinating C enter ( SDCC ) for th e trial. 
Reasons for screen failure or no enrollment and dosing of an eligible subject will be listed in the 
MOP and also be entered in the system. Instructions for using the enrollment module are included in the Advantage eClinical
® User’s Guide.  
Since this is an open-label study of a single dose of IMP, subjects will be enrolled on a rolling 
basis. Four s ubjects will be assigned to each one of five cohorts, T1 -T5 (Section  4), for lung PK 
with equal allocation (1:1:1:1:1) and registered into  the Advantage eClinical®. Each cohort 
corresponds to a single Lung PK sampling timepoint. It is planned to enroll subjects into cohorts 
T1 to T4 according to availability of the bronchoscopy suite. However, on the day of 
bronchoscopy, a subject may be reassigned to another cohort than planned on the same day, 
depending on emergencies at the bronchoscopy suite at the time originally planned, or cancelled.   
Appointments for the bronchoscopy procedure wil l be made in advance and e very effort will be 
made to admi t, dose and perform bronchoscopy with BAL according to the schedule. However, 
if a scheduled bronchoscopy cannot be performed according to schedule on a dosing day, the 
following steps may be taken  according to the time of cancellation before or after dosing : 
• If the procedure is cancelled before administration of study drug, an effort will be made 
to reschedule the procedure.  
• If the procedure is cancelled after  administration of the study drug, bronchoscopy may be 
either rescheduled  if it can be performed at a later time that c an accommodate an 
available Lung PK timepoint up to 8 h after dosing or cancelled . 
o If bronchoscopy is rescheduled, the registration in the Advantage eClinical® will be 
updated to indicate the cohort that the subject completed  and a future subject would 
be assigned in the registry to complete the missed Lung PK timepoint.  
o If it is not feasible to res chedule bronchoscopy, the subject will be terminated from 
participation in the study and will be replaced. The subject will be asked to  remain in 
the study to complete safety and otoacoustic testing  until Final Visit (Day 30  ± 4 
days) . If the subject decli nes to remain in the study for safety assessments, 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     43 appropriate early termination assessments will be completed prior to discharge from 
the CTU. ( See Section 5.3.3 and Section  7.7) 
 Reasons for Withdrawal and Discontinuation of Study Drug  Administration  
A subject may withdraw from the trial at any time for any reason, without any consequences. 
A subject will be discontinued from the trial if any of the following occur before  dosing: 
• Request by [CONTACT_92237] . 
• Failure to receive the study drug due to difficulty initiating or maintaining an intravenous 
infusion line. 
A subject may be removed from the trial after dosing for the following reasons; however, 
whenever possible, the subject will be followed for safety per protocol to Day 30 (± 4 days): 
• Failure to adhere to protocol requirements. 
• Loss to follow-up. 
• Request of primary care provider. 
• Request of the Institutional Review Board (IRB)/Ethics C ommittee  (EC), FDA or DMID . 
• The subject’s well -being, based on the opi[INVESTIGATOR_871]. 
• The occurrence of an SAE or TEAE warranting withdrawal. 
• Failure to receive the entire volume of apramycin  solution during the designated infusion 
time. 
 Handling of Withdrawals and Discontinuation of Administration 
• Subjects who are withdrawn before dosing may be replaced with a subject assigned to the same lung PK timepoint group (T1 -T5).  
• Subject s who did not receive the entire infusion volume of apramycin  will be replaced 
and withdrawn  from bronchoscopy and associated procedures and from PK analysis but 
will be encouraged to continue follow up for safety . 
• Subjects who withdraw after receiving the entire study treatment but before the scheduled 
bronchoscopy and associate procedures will be replaced and withdrawn from the study 
and data analysis but will be followed for safety .  
• Subjects who withdraw after receiving the entire study treatment and completed 
scheduled bronchoscopy and assessments will not be replaced  unless more than 50% of 
subjects in  a Lung PK timepoint cohort are withdrawn from the trial.   
• Generally, subjects who received the entire amount of the study drug but withdraw from 
the trial will be encouraged to continue follow- up (with subjects’ consent) for safety  
assessments and plasma  PK sample collection .  
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     44 • Subjects withdrawing will be asked to complete safety and otoacoustic testing according 
to the ET schedule (See  Section 7.7) .  
 Lost to Follow- up 
If subjects fail to appear for a follow -up assessment, extensive effort (i.e., three documented 
contact [CONTACT_92238], e- mail, etc., made on separate occasions and followed by a 
certified letter) will be made to locate or recall them, or at least to determine their health status. These efforts will be documented in the subjects’ records. 
 Termination of Study  
Although DMID  has every intention of completing the trial, it reserves the right to terminate the 
trial at any time for clinical or administrative reasons.  In addition, the trial may be terminated or 
suspended at the request of the FDA, SMC or IRB/ EC. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     45 6 STUDY INTERVENTIO N/INVESTIGATIONAL 
PRODUCT 
6.[ADDRESS_601712] : Apramycin (EBL-1003) 
The active drug substance apramycin is chemically a monosubstituted 2-deoxystreptamine. It is 
manufactured as crystalline free base by [CONTACT_469396] (CAS [ZIP_CODE]-09-8). Apramycin sulfate is manufactured by [CONTACT_469397] 
(Streptoalloteichus tenebrarius ) by [CONTACT_469398]- Phar Pharmaceutical Co, China and 
then recrystallized to apramycin free base an d purified by [CONTACT_469399] (RISE). 
Drug Substance is then formulated and bottled by [CONTACT_469400], Italy (a Thermo Fisher 
Scientific company) for Juvabis AG, the pharmaceutical sponsor of the study. 
The diluent for apramycin will be 0.9 % sodium chloride injection, USP. The USP grade 0.9% 
Sodium Chloride Injection, or normal saline, is a sterile, nonpyrogenic, isotonic solution; each 
mL contains sodium chloride 9 mg. It contains no bacteriostatic agent, antimicrobial agent, 
preservatives, or added buffer and is supplied only in single-dose vials. The solution may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 5.3, range 4.5 to 7.0). This product should be used to dilute apramycin to the desired concentration. 0.9% sodium chloride 
for injection, USP is clear in color.  
 Acquisition  
Product: Apramycin (EBL-1003) 
Upon request by [CONTACT_122830], study product will be shipped for clinical labeling from a German location supplied by [CONTACT_469401] (a Clinigen company) to the following address:    
DMID -Clinical Materials Services (CMS)  
Fisher BioServices  
[ADDRESS_601713] 
Germantown, MD [ZIP_CODE] 
Tel: [PHONE_6136] 
Fax: [PHONE_6137] 
E-mail: [EMAIL_1395]    
The diluent, 0.9% Sodium Chloride Injection, USP, will make up the infusion volume (30 mL) 
and will be  provided by [CONTACT_258830]. Details will be provided in the protocol-
specific Manual of Procedures (MOP). 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601714] and approval by [CONTACT_122830]. 
Details will be provided in the protocol- specific MOP.  
Ancillary supplies required for IV administration (including syringes or infusion bag, tubing and 
IV catheter  and line -filter) will be supplied by [CONTACT_469402]- specific MOP.  
 Formulation, Packaging, and Labeling 
Product: Apramycin (EBL-1003) 
Apramycin for In fusion, the IMP, is formulated as 150 mg free base /mL in sterile aqueous 
solution, pH 5.[ADDRESS_601715] is supplied in 20 mL glass vials . A volume of ≥[ADDRESS_601716] the solution from light, 
the vials are stored in folding boxes. 
The clinical research site will provide the diluent, 0.9% sodium chloride injection, USP. 
Commercial source, product information and packaging will be described in the MOP.  Each product vial and diluent will be labeled in compliance with applicable regulatory 
requirements, including the FDA-required cautionary statement, “Caution – New drug – Limited 
by [CONTACT_4496] (or [LOCATION_002]) Law to Investigational Use”.  
 Product  Storage and Stability 
Product: Apramycin (EBL-1003) 
Apramycin  for Infusion will be shipped refrigerated at +5  ± 3°C (35.6 to 46.4°F) and should be 
stored refrigerated at 2 to 8°C (35.6 to 46.4°F) within the packaging until time of preparation. 
Protect from freezing. The reconstituted solution must be stored at 2 to 25°C (storage at 2  to 8° C 
if possible) and used within [ADDRESS_601717] accountability as pe r Section 6.4.  
The diluent, 0.9% NaCl for injection, USP, will be stored per manufacturing instructions. Product storage and stability will be described in the MOP. 
The clinical supplies storage area at the CTU  will be monitored by [CONTACT_469403]. Documentation of temperature monitoring will be maintained.  
6.2 Dosage, Preparation , and Administration  of Study Intervention/  
Investigational Products  
The site Research Pharmacist (RP) will prepare the study product on the same day as administration. The study drug will be inspected  for damage, contamination, discoloration, or 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     47 particulate matter  before use. Any study drug that fails inspection will be quarantined at 
appropriate temperature and labeled ‘Do Not Use’ until further notice. The S ite Principal 
Investigator ( PI) or responsible person will immediately contact [CONTACT_469404] (CPM) and study clinical team for further instructions before administering any 
additional study drug infusions. Based on the information collected, DMID and/or Juvabis AG 
will determine whether the affected study drug can be used. If it cannot be used, the CTU will receive specific instructions on how to return it to DMID CMS or destroy it on site.  
Preparation of the product will be performed using aseptic technique under a sterile environment 
(e.g., Biologic Safety Cabinet or laminar flow hood). Each subject w ill receive 30 mg/kg of 
apramycin in a volume of 30 mL as a single IV infusion over 30 (± 5) min utes in a hand or 
forearm vein using a syringe or infusion pump. Based on the subject weight, the appropriate 
weight- based apramycin for infusion dose will be calculated and the appropriate number of vials 
will be removed from storage to prepare the infusion. Sterile normal saline will be used to adjust the volume. 
The subjects will be admitted to the Phase [ADDRESS_601718] will prepare the 
infusion as described in the protocol- specific MOP. Apramycin for infusion should be 
administered as a single IV infusion over 30 min (± 5) using a syringe or infusion pump via a 
hand or forearm vein. The drug should not be administered as a bolus. The IV administration set 
must contain a 0.[ADDRESS_601719] and handling of infusion interruptions. 
6.3 Modification of the Study Intervention/  Investigational Products  
Not applicable for single-dose study drug trial. See Study Halting Criteria , Section 9.5.1. 
Handling of infusion interruptions will be reported in the MOP. 
 Overdose  
An overdose is defined as a dose greater than the high- dose level evaluated in the trial. All 
overdoses will be repor ted as a deviation; if the overdose is associated with a TEAE, then the 
TEAE will also be reported. In the event of an overdose of apramycin , the Investigator will use 
clinical judgment in treating the overdose and contact [CONTACT_434382] (MM). Th ere 
is no specific antidote in case of apramycin overdose. The same measures as recommended for other aminoglycosides (treatment cessation, adequate hydration, dialysis, administration of 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     48 calcium salts for neuromuscular blockade) would be considered until further clinical data are 
available for apramycin . (IB 2021) The investigator will refer to the relevant document(s) for 
detailed information regarding warnings, precautions, contraindications, TE AEs, and other 
significant data pertaining to apramycin . Such documentation may include but not be limited to 
the IB.  
6.4 Accountability Procedures for the Study Intervention/  
Investigational Products   
The S ite PI [INVESTIGATOR_469354]. The S ite PI [INVESTIGATOR_469355] S ite RP . If 
delegated, the S ite R P will be responsible for maintaining complete records and documentation 
of the study drug’ s receipt, accountability, dispensation, temperature monitoring, storage 
conditions, and final disposition. Time of study drug administration to the subject must be 
recorded on the appropriate data collection form ( DCF ). 
All study drugs, whether administered or not, will be documented on the appropriate study drug 
accountability record or dispensing log. Used and unused apramycin  vials will be retained until 
monitored. Upon completion of the trial and after the final monitoring visit, any remaining unused study drugs will either be returned or destroyed appropriately at the CTU as per DMID requirements and instru ctions that will be communicated to the CTU by [CONTACT_469405] . 
Unused apramycin vials will be released for disposition per DMID requirements. DMID does not 
require used containers of study product to be maintained at the research pharmacy, except when 
the local institution’s SOP/policy mandates retaining used IV vials.  If local SOPs allow 
destruction of used study product containers, the used vials can be destroyed per the site’s SOPs; 
a second staff member must observe the destruction and sign verification (two signatures) that 
the used vials were discarded . 
Any unused solution left in the IV infusion syringe or bag or the IV administration tubing after 
administration to the subject should be discarded as biohazardous waste. If a container of study 
product is unusable due to breakage, or any other reason, this explanation should also be noted 
on the Study Product Accountability Record (e.g., broken – dropped on floor). Details will be provided in the MOP.  
6.[ADDRESS_601720] Compliance with the Study Intervention/  
Investigational Products  
Since each dose of apramycin  will be administered by [CONTACT_8786], subject compliance is not 
anticipated to be an issue. Complete information regarding any partial or interrupted dosing will be documented. Subj ects unable to receive the full volume of apramycin  infusion will be 
withdrawn from data analysis and followed up for safety as described in Section 5.3.3.   
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     49 6.6 Prior and Concomitant Medications/Treatments  
Medications include the following: prescription drugs, birth control hormonal preparations, non-
prescription medication , herbs, vitamins, nutritional supplements, and illicit and recreational 
substance s.  
Medications taken before or after dosing will be reported as Prior M edication s or Concomitant 
Medications  (ConMeds) , respectively .  
Prior prescription medication s will be  recorded at Screening Visit. All prior medications are 
not allowed during the study period with the  exception of oral contraceptives, which are 
permitted throughout the study, and solitary doses of up to 1,000 mg acetaminophen 
(paracetamol) . 
The following medications are prohibited for the indicated periods prior to dosing: 
• Use of any investigational drug product within 30 days or 5 half-lives (whichever is 
longer) before dosing or planned use during the study period (screening until Final Visit). 
• Use of aminoglycosides within 3 months prior to dosing. 
• Use of neuromuscular blocking agents within 1 week or 5 half-lives (whichever is longer) prior to dosing. 
• Use of potentially nephrotoxic medication 2 weeks prior to dosing: Renin – angiotensin-
aldosterone system [RAAS] inhibitors: angiotensin-converting enz yme [ACE] -inhibitors, 
angiotensin II [AII]-receptor antagonists (enalapril, lisinopril, ramipril captopril, benazepril) , spi[INVESTIGATOR_8407], eplerenone; non- steroidal anti-inflammatory drugs [NSAIDs] 
(aspi[INVESTIGATOR_248], ibuprofen, naproxen, indomethacin, etc.) including cyclooxygenase 2 [COX- 2] 
selective inhibitors  (Bextra, C elebrex, Vioxx).  
• Use of potentially ototoxic medication 3 months prior to dosing: vancomycin, loop diuretics  (bumetanide, ethacrynic acid,  furosemide), quinine and quinidine derivatives 
including mefloquine with the exception of occasional intake of quinine containing beverages.  
Non-prescription medications, herbs , vitamins, and nutritional supplements will not be t aken 
within 15 days before  dosing and during the trial. Exceptions : vitamins and OTC medications 
taken for < 48 h for the treatment of common symptoms (e.g., headache, indigestion, muscle pain) may be allowed if  approved by [CONTACT_469406]. 
Blood/blood products  (RBCs, WBCs , platelets, and plasma) donation of 500 mL within 
3 months or more than 100 mL within 30 days before signing informed consent to this trial is not allowed, and it is prohibited during the course of this trial. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     50 Following dosing, each new ConMed and changes to existing medications will be recorded. 
Subjects will be required not to utilize non-study medications during the trial except those deemed necessary by [CONTACT_7910] [INVESTIGATOR_11637]- investigator.  
Any drug (e.g., non-prescription medications, herbal supplements , vitamins , or prescription 
medications ) or vaccines or blood/blood products used by [CONTACT_469407]’s source documents and on the appropriate electronic case repo rt form 
(eCRF ), and the PI [INVESTIGATOR_469356] (listed on FDA Form 1572) will note whether 
the use was medically indicated and immediately necessary . Any use of medications not 
authorized by [CONTACT_9154] [INVESTIGATOR_469357] a s a deviation.  
6.[ADDRESS_601721] to adhere to the following restrictions during participation in the study. 
 Smoking  
Smoking is prohibited during the in-patient period of the study (Day -2 to discharge on Day 3) and should be avoided during the out- patient follow -up period until the last visit (Day 30 ± 
4 days).  
 Physical Activity  
Subjects will be counseled to re frain from rigorous physical activity starting 2 days before dosing 
until discharge from the CTU on Day 3, and 24 h before each follow-up visit (Day 14 ± 3 days 
and Day 30 ± 4 days ).  
 Food and Fluid intake  
Subjects will be provided food and non-alcoholi c beverages by [CONTACT_941] C TU during the dosing period 
of the trial. Subjects will fast at least 6 hours prior to blood draw on days of clinical laboratory 
testing (screening, Day  -2, Day 1 [pre-dose], Day 2, Day 3 and Day 14 [± 3 days]). Subjects will 
fast for at least [ADDRESS_601722] 2 L daily from the time of dosing to 48 h (Day 2) after dosing, and the time and amount consumed will be recorded .   
 Alcohol, Marijuana and Illicit Drugs 
Subjects  will have to agree to consume not more than 24 g  (men)/ 12 g (women) pure alcohol per 
day from Screening to enrollment (Day - 2) and from the day of di scharge from t he CTU on 
Day 3 to Day 30 ± 4 days (final visit). Alcohol will not be served during the in-patient period 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601723] to avoid exposure to loud noise (e.g., construction sites, visiting concerts or dance 
events, fireworks , listening to music or playing videogames with headphones ) from screening 
until Day 30 ± 4 days (final visit).  
 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601724] database and IRB -approved advertisements and social media. IRB-approved, 
prescreen ing questionnaires will be used to determine if subjects meet study requirements before  
scheduling screening visits. 
7.2 Screening Visit (Day -28 to Day -3) 
This will be an out- patient visit to complete the following  within 2 8 days before study drug 
dosing:  
Note:  A second screening visit may be scheduled to complete Otoacoustic screening tests to 
accommodate subjects’ personal schedule. 
• Obtain informed consent. 
• Assign a study ID number to subjects who consent to participate . 
• Record demographics including age, gender, race, and ethnicity. 
• Obtain contact [CONTACT_3031]. 
• Obtain height and body weight, and calculate Body Mass Index (BMI; wt [kg] / ht [m2]) 
• Take VS (supi[INVESTIGATOR_345208] [ADDRESS_601725] olic BP  [SBP and D BP], 
heart rate [ HR], respi[INVESTIGATOR_697]  [RR], and oral temperature [T]). 
• Obtain M edical History (MH).   
• Review history of P rior Medications .  
• Perform complete Physical Examination ( PE). 
• Obtain blood and urine samples for screening clinical laboratory tests  that include a 
calculation of Glomerular Filtration Rate (GFR) by [CONTACT_91019] -EPI [INVESTIGATOR_10908]. 
• Obtain blood samples for viral serology (HIV antibody, HBsAg, HCV antibody).  
• Obtain serum for β -HCG pregnancy test from all women.  
• Obtain serum for FSH level from only post- menopausal women .  
• Obtain urine sample for illicit drugs and drugs of abuse (urine drug screen), and cotinine. 
• Perform alcohol breathalyzer test .  
• Obtain a single 12-lead ECG with 10- sec rhythm strip . 
• Perform spi[INVESTIGATOR_038] . 
• ENT Examination that includes: 
o Ear Otoscopy. 
o Valsalva test . 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     53 o Tympanometry. 
o Stapedial Reflexes . 
• Cochlear (Hearing) Examination that includes: 
o Ear Audiometry (pure tone audiometry). 
o Distortion Product Otoacoustic Emissions ( DPOAEs ). 
• Counsel on use of contraception ( males and females) , avoidance of pregnancy (women of 
childbearing potential), avoidance of prohibited medication, illicit drugs, alcohol, 
nicotine products, vigorous exerci se, and exposure to loud noises). 
• Confirm eligibility . 
Subjects who meet the eligibility criteria of the otoacoustic assessments will be contact[CONTACT_469408] - [ADDRESS_601726] positive for 
HIV antibody, HBsAg, and/or HCV antibody, they will be informed that test results may be 
reported to the local health authorities according to state or local law. 
Subjects who fail the otoacoustic screening will be informed of the findings and counseled to 
seek medical care by [CONTACT_469409]. 
Subjects who fail screening assessments on either one of these visits will not be rescreened 
unless they had an inter-current, short- term medical illness. Subjects who meet eligibility criteria 
but could not be enrolled within permissible window may be rescreened. 
7.3 Check -in (Day  -2)    
Subjects meeting all  inclusion and no exclusion criteria at Screening Visit will check into the 
CTU on Day  -2 and the following procedures will be performed: 
• Review inclusion/exclusion criteria to confirm the subject remains eligible for admission . 
• Update MH . 
• Update Prior Medications.  
• Obtain VS .  
• Obtain body weight. 
• Perform complete PE .  
• Obtain blood and urine samples for clinical laboratory tests that include a calculation of 
GFR  by [CONTACT_91019]- EPI [INVESTIGATOR_10908]  (for determining eligibility) . 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     54 • For all women, a urine β -HCG pregnancy test will be done, and negative results 
confirmed before dosing. 
• Obtain urine sample for illicit drugs and drugs of abuse (urine drug screen) and cotinine. 
• Perform alcohol breathalyzer test .   
• Obtain sample for serum Cystatin -C. 
• Obtain sample for urinary KIM-1.  
• Obtain a single 12-lead ECG with 10- sec rhythm strip . 
• Perform otoacoustic assessments . 
o Ear otoscopy. 
o Audiometry (pure tone audiometry including high frequencies). 
o DPOAEs . 
Note: Day -2 otoacoustic assessments may be completed on Day - 4 or Day -3 as if needed .  
• Admit eligible subjects in the CTU. 
• Counsel to avoid rigorous physical activity, encourage good hydration, a void caffeinated 
beverages  and exposure to loud noises.  
7.4 Baseline ( Day -1) 
Admitted subjects will have the following assessments: 
• Review inclusion/exclusion criteria , before 12-lead ECGs, to confirm the subject remains 
eligible for enrollment. 
• Update MH . 
• Update Prior Medications.  
• Obtain VS . 
• Perform abbreviated PE .  
• Assign subject to Lung PK timepoint cohorts (T1 -T4) and enroll in Advantage 
eClinical®. 
• Obtain baseline 12- lead standard ECG with 10- sec rhythm strip  in triplicate  at the same 
timepoints a s the projected timepoints for ECGs to be recorded before and after dosing on 
Day 1  (within 30 min before and 1 h [± 5 min ], 4 h [± 10 min], and 16 h [± 15 min] after 
start of dosing).     
• Counsel to avoid rigorous physical activity, encourage good hydration, a void caffeinated 
beverages .  
  
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     55 7.5 Inpatient Treatment Period (Days 1 to 3)  
 DAY 1: Administration of Study Drug  – Bronchoscopy (Cohorts T1 – T4) 
Before Dosing:   
• Withhold breakfast or food at least [ADDRESS_601727] assignment into one the Lung PK cohorts (T1 -T5).  
• Allow access to water.   
• Review inclusion/exclusion criteria to confirm  the subject remains eligible for dosing. 
• Update MH .  
• Update Prior Medication s and review any new medication. 
• Obtain VS within 30 min before dosing (baseline) . 
• Perform symptom- directed PE . 
• Obtain 12- lead standard ECG with 10 -sec rhythm strip in triplicate within 30 min before 
dosing.  
• Insert IV catheter for blood collection into a hand or forearm vein . 
• Insert IV line for study drug infusion into a vein in the other forearm. 
• Obtain blood and urine samples for clinical laboratory tests that include a calculation of 
GFR by [CONTACT_91019]-EPI [INVESTIGATOR_10908] (for baseline). 
• Obtain sample for serum Cystatin -C (for baseline) . 
• Obtain sample for urinary KIM- 1 (for baseline). 
• Obtain pre -dose blood (plasma) PK sample for total apramycin within 30 min before 
starting administration of study drug. 
o Measure pre -dose urea concentration in an aliquot of the blood 9plasma) PK sample 
collected within 30 min before starting administration of study drug. 
Note  1: If 12-lead standard ECGs, VS  assessments,  and PK blood draws to be done at the 
same timepoint before or after dosing, these procedures will be performed  in this  
order: 12-lead standard ECG, VS,  and PK blood draw.  
Note 2 : In cohort T3, obtain ECG , VS and PK draws at the 4 h timepoint before  
administration of sedation or anesthetic for BAL.  
Note 3: CTU staff may complete pre-dosing procedures in the bronchoscopy ward instead of 
the CTU to enable timely initiation of bronchoscopy at 0.5 h (± 5 min) after initiation 
of the dosing in subjects assigned to cohort T1 .   
Dosing:  
• Administer a single  30 mg/kg body weight dose of apramycin as a single IV infusion 
with a syringe or infusion pump over 30 ( ± 5) min utes in a forearm vein , as described in 
Section 6.2. 
• Initiate TE AE assessments (excluding laboratory events) and SAE assessments . 
• Perform focused PE (for TEAE assessments) . 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     56 • Initiate recording of ConMeds. 
• Withhold food until [ADDRESS_601728] assignment into one of the Lung PK cohorts (T1 -T5).   
• Allow access to water . 
After Dosing : 
• Bronchoscopy with BAL once per subject at the following nominal timepoints after 
starting IMP infusion according to the assigned cohort: 0.5 h (± 5 min) (T1),  2 h (± 5 min) (T2), 4 h (± 10 min) (T3) and 8 h (T4) (± 15 min) .   
o Transfer s ubject to the UTMC bronchoscopy suite accompanied by [CONTACT_469410] . 
 Note: Subjects in T1 may  start receiving study drug in the bronchoscopy suite. 
o Collect scheduled safety information before and after the procedure in the 
bronchoscopy suite and during the recovery period.  
o Monitor subject before and after the procedure per orders by [CONTACT_469411].  
o Transfer subject to the CTU from the UTMC bronchoscopy suite accompanied by 
[CONTACT_469410] . 
o Collect BAL samples for the measurement of total apramycin concentration and 
estimate of PK parameters once per subject at the assigned timepoint above, as described in S ection 8.5, corresponding to the assigned cohort: 0.5 h (±  5 min) (T1), 
2 h (± 5 min) (T2), 4 h (± 10 min) (T3) and 8 h (T4) (± 15 min) a fter initiation of 
dosing. Details on processing the BAL samples and preparation of ELF  and AM 
samples for apramycin concentration measurements and PK analysis will be provided in the MOP . 
Note  1: Collect  plasma samples for total apramycin concentration within 5 min of the 
corresponding BAL procedure at 0.5 h (± 5 m in),  
2 h (±  5 min), 4 h (± 10 min) , or 8 h (± 15 min)  after initiation of the infusion. If 
collection of BAL samples is delayed, plasma samples will be collected at the 
indicated nominal timepoint (and allowable windows), as described above, and an additional plasma PK will be collected within [ADDRESS_601729] BAL sample .   
Note 2 : Measure urea concentration at the same timepoint as the nominal timepoint of 
plasma PK or in the plasma sample that is collected within [ADDRESS_601730] onto study CRF will be described in the MOP.  
• Check infusion site (during and end-of-infusion, and 1 h ( ±5 min ) and 16 h (± 15 min ) 
after the infusion for infusion site reactions. Details will be provided in the MOP. 
• Obtain 12-lead standard ECG with 10-sec rhythm strip in triplicate at 1 h  (±5 min) , 4 h 
(±10 min) and 16 h (±15 min) after dosing. Record ECG before VS and PK draws and, at 
4 h, before administration of sedation or anesthetic for BAL  in cohort T3. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     57 • Obtain VS at 1 h (±5 min), 4 h (±10 min) and 16 h (± 15 min) after dosing:  
o Note: More frequent monitoring will be at the PI’s discretion based on subject’s 
clinical status after bronchoscopy.  
• Obtain blood (plasma) PK samples for total apramycin at 0.5 h (±5 min, immediately at 
the end of infusion), 1 h (±5 min), 2 h (±5 min), 4 h (±10 min), 8 h (±15 min), and 16 h 
(±15 min) after initiating the IMP infusion.  
o Note 1 : An aliquot of plasma PK collected at 0.5 h (±5 min; immediately after the end 
of infusion) after starting the IMP infusion will be used for the protein binding test 
(for measurement of free apramycin ).  
o Note 2 : An aliquot of plasma PK collected at 0.5 h (±5 min) after  starting the IMP 
infusion will be used for the measurement of urea.  
• Monitor subject closely until fully recovered per bronchoscopy instructions. 
o Provide oxygenation as needed. 
• Perform TEAE assessments (excluding laboratory events) and SAE assessments . 
• Document ConMeds . 
• Do not provide solid food until at least [ADDRESS_601731] is able to 
swallow.  
• Encourage water intake at least 2 L daily  – Document time and volume consumed . 
• Counsel to avoid rigorous physical activity and avoid caffeinated beverage s. 
 DAY 2: Inpatient Follow- up – Bronchoscopy T5 
For a subject assigned to lung PK timepoint group T5:  
• Perform bronchoscopy with BAL on Day 2 at 24 h (± 1 h) after dosing as described for 
subjects in cohorts T1 -T4 ( see Section  7.5.1, Day 1, After Dosing ). 
o Collect BAL samples for PK analysis once per subject at the assigned timepoint, 24 h 
(±1 h) (T5) after initiation of dosing, as described in Section 8.5, corresponding to the 
assigned cohort T5.  Note 1 : Collect plasma sample for total apramycin concentration within 5 min of the 
corresponding BAL procedure at 24 h (± 1 h) after initiation of the infusion. If 
collection of BAL samples is delayed, plasma sample will be collected at the 
indicated nominal timepoint (and allowable windows), and an additional plasma PK will be collected within [ADDRESS_601732] BAL sample.  (See Section 8.5.1 ) 
Note 2 : Urea will be measured in plasma collected at the same nominal timepoint as 
the plasma PK sample or in the plasma PK sample that is collected within [ADDRESS_601733] BAL sample . 
• Monitor subject closely until fully recovered per bronchoscopy instructions. o Provide oxygenation as needed. 
For all subjects: 
• Obtain single 12-lead standard ECG with 10-sec rhythm strip at 24 h (±1 h) and 36 h  (±1 h) after dosing . 
• Obtain VS  at 24 h (± 1 h) and 36 h (±1 h) after dosing. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     58 • Obtain blood (plasma) PK samples for total apramycin at 24 h (±1 h) and 36 h (±  1 h) 
after dosing. 
o An aliquot of plasma PK collected at 36 h (±1 h) after starting the IMP infusion will be used in the protein binding test ( for the measurement of free apramycin ). 
• Obtain blood and urine samples for safety clinical laboratory tests that include a calculation of GFR by [CONTACT_91019]-EPI [INVESTIGATOR_469358] 24 h (±1 h) after dosing. 
• Check on infusion site at 24 h (±1 h) and 36 h (±1 h) after dosing. 
• Perform TEAE and SAE assessments. 
• Perform symptom- directed (focused ) PE for evaluation of TEAEs as needed. 
• Document ConMeds. 
• Encourage water intake at least 2 L daily – Document time and volume consumed. 
• Counsel to avoid rigorous physical activity and avoid caffeinated beverages.  
 DAY 3: I npatient Follow- up 
• Obtain 12-lead standard ECG with 10-sec rhythm strip at 48 h (±1 h) and 60 h (±1 h) 
after dosing.  
• Obtain VS at 48 h (±1 h) and 60 h (±1 h) after dosing. 
• Obtain blood (plasma) PK samples for total apramycin at 48 h (±1 h) and 60 h (±1 h) 
after dosing.  
• Obtain blood and urine samples for clinical laboratory tests that include a calculation of GFR by [CONTACT_91019]-EPI [INVESTIGATOR_469358] 48 h (±1 h) after dosing . 
• Obtain blood sample for Cystatin C and urine sample f or KIM -1 (exploratory biomarkers 
of renal injury) at 48 h (±1h) after dosing . 
• Perform otoacoustic assessments .  
o Ear otoscopy. 
o Audiometry (pure tone audiometry including high frequencies). 
o DPOAEs . 
Note : Day -2 otoacoustic assessments may be completed on Day 3 (+2  days) if needed.  
• Check on infusion site at 48 h (±1 h) and 60 h (±1 h).  
• Perform TEAE and SAE assessments .  
• Document ConMeds.  
• Perform complete PE .  
• Counsel on use of contraception (males and females), avoidance of pregnancy (women of 
childbearing potential), avoidance of prohibited medication, illicit drugs, alcohol, nicotine products, vigorous exercise, and exposure to loud noises. 
• Instruct on the next scheduled visit.  
• Discharge subject f rom the CTU after review of clinical laboratory tests, ECGs and other 
assessments by [CONTACT_976] [INVESTIGATOR_469359].  
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     59 Note  1: If the time of discharge is late in the evening, due to delays in starting procedures on 
Day 1 or personal reasons (such as distance from residence), the subject may stay in the CTU 
overnight and be discharged the following morning.  Note 2 : If otoacoustic assessments could not be performed on Day 3, the subject will be 
discharged from the CTU on Day 3 after all other assessments are completed. Otoacoustic assessments will be completed up to Day 3 (+2 days) as outpatient. 
7.6 Outpatient Follow-up Period (Days 14 and 30)  
Subjects will return to the CTU to have the following assessments: 
 DAY 14 (±  3 days) 
• Obtain 12-lead standard ECG with 10-sec rhythm strip. 
• Obtain VS . 
• Obtain blood and urine samples for clinical laboratory tests that include a calculation of 
GFR by [CONTACT_91019]- EPI [INVESTIGATOR_10908] .  
• Obtain blood sample for Cystatin C and urine sample for KIM-1 (exploratory biomarkers of renal injury). 
• Perform otoacoustic assessments . 
o Ear otoscopy. 
o Audiometry (pure tone audiometry including high frequencies). 
o DPOAEs . 
• Check on infusion site.  
• Perform TEAE and SAE assessments. 
• Document ConMeds.  
• Perform a complete PE . 
• Counsel on use of contraception (males and females), avoidance of pregnancy (women of 
childbearing potential), avoidance of sperm donation, avoidance of prohibited 
medication, illicit drugs, alcohol, nicotine products, vigorous exercise, and exposure to loud noises. 
• Instruct on the next scheduled visit.  
 Day 30 (± 4 days) – FINAL VISIT  
• Perform TEAE and SAE assessments . 
• Document ConMeds.  
• Obtain blood sample for Cystatin C and urine sample for KIM-1 (exploratory biomarkers 
of renal injury).  
• Perform symptom-directed (focused PE) for evaluation of TEAEs as needed. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     60 • Perform otoacoustic assessments . 
o Ear otoscopy. 
o Audiometry (pure tone audiometry including high frequencies). 
o DPOAEs .  
• Discharge subject from the study.  
• Follow up on-going TEAEs including otoacoustic abnormalities according to PI 
[INVESTIGATOR_469360]. 
7.7 Early Termination  (if needed)  
• Obtain VS . 
• Obtain weight. 
• Check infusion site. 
• Perform complete PE .  
• Perform TEAE and SAE assessments . 
• Update ConMeds. 
• Obtain single 12- lead standard ECG with 10 -sec rhythm strip . 
• Obtain blood and urine for clinical laboratory tests that include a calculation of 
Glomerular Filtration Rate (GFR) by [CONTACT_91019] -EPI [INVESTIGATOR_10908]. 
• Obta in blood sample for Cystatin C and urine sample for KIM -1 (exploratory biomarkers 
of renal injury).  
• Obtain blood PK sample for total apramycin  if ET occurs within 24 h of dosing. 
• Perform otoacoustic assessments (ear otoscopy, audiometry [pure tone audiometry 
including high frequencies], and  DPOAEs ). 
• Counsel on use of contraception (males and females), avoidance of pregnancy (women of 
childbearing potential), avoidance of sperm donation. 
7.8 Unscheduled Visit  (if needed)  
A subject may return to the clinic for an unscheduled visit at any time after discharge on Day 3 . 
The following activities at a minimum will be performed:  
• Perform TEAE and SAE assessments . 
• Update ConMeds. 
• Obtain VS . 
• Perform symptom-directed (focused) PE, if applicable. 
• Obtain blood and/or urine for clinical safety laboratory tests  that include a calculation of 
GFR by [CONTACT_91019]- EPI [INVESTIGATOR_10908] , if applicable . 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     61 • Obtain single 12- lead standard ECG with 10 -sec rhythm strip as needed for the 
evaluation of a TE AE, if applicable. 
• Perform otoacoustic assessments, if applicable ( Ear otoscopy, Audiometry [pure tone 
audiometry including high frequencies] , and DPOAEs ). 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     62 8 STUDY PROCEDURES/EVALUATIONS 
8.1 Clinical Procedures/E valuations  
 Informed Consent  
The informed consent form ( ICF) will be approved by [CONTACT_3488] /EC and executed 
before  performing any study- related activities.  
Informed consent will be obtained for all subjects participating in the trial before performing any 
screening assessments . Subjects may withdraw consent a t any time. Participation in the trial may 
be terminated at any time without the subject’s consent as determined by [CONTACT_737].  
 Demographics  
Demographic information (date of birth, gender, ethnicity and race) will be recorded on the 
subject’s source documents and e CRF at S creening Visit. Name, address, phone number, and 
emergency contact [CONTACT_469412]. 
 Inclusion/Exclusion Criteria  
Eligibility screening of healthy subjects will be completed within [ADDRESS_601734]’s source documents and e CRF. Review of 
inclusion and exclusion criteria will be performed on Day - [ADDRESS_601735] remains eligible for dosing. 
Screening failures and the reason for failure to meet the study eligibility requirements will be 
documented in the source documents and entered into the study database.  
 Medical History  
For subjects enrolled in the trial, the medical history ( MH) will be obtained by [CONTACT_469413]’s source document and e CRF. The MH will capture 
the subject’s current disease proces ses, past disease processes, history of hospi[INVESTIGATOR_059], history 
of surgery, allergies, and prior medications  (see Section 6.6). Subjects will be queried regarding 
a history of significant medical disorders of the head, eyes, ears, nose, throat (HEENT), mouth, 
skin, and the cardiovascular , gastrointestinal, renal , urologic al, nervous, hematological, 
lymphatic, endocrine, musculoskeletal , and genital/reproductive systems. A history of hearing 
abnormalities or hearing loss, especially following administration of aminoglycoside antibiotics 
or other medications, kidney disorders, cardiovascular disorders, including MI and angina, 
cardiac arrhythmias including Long QT Syndrome ( LQTS ), syncope due to cardiac arrhythmias 
or unexplained, psychiatric illness, and substance abuse will be specifically solicited. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     63 Occupational history of exposure to loud noise will be obtained. Family history of hearing loss, 
especially on the maternal side, renal disorders, and sudden death will be obtained. T he MH  will 
be obtained at S creening Visit and updated upon admi ssion  to the CTU  at check -in (Day -2), on 
Day -1, and before dosing on Day 1. After start of study drug dosing, any worsening of pre-
dosing MH  or new symptoms will be evaluated and reported as TEAEs.  
 Physical Examination 
A complete PE  – except  genital, breast , and rectal exam s – will be performed at the Screening 
Visit, check -in visit ( Day -2), Day 3 , and Day 14 (± 3 day s) after dosing, or ET Visit, and will 
assess general appearance, HEENT, heart, lungs, abdomen, skin, m usculoskeletal  system , and 
lymph nodes, and a standard neurological exam. 
An abbreviated PE  will be performed at Day -1. An abbreviated PE differs from a complete PE 
in that the abdomen and  neurological system are not evaluated .  
A symptom- directed (focused) PE  may be performed before dosing on Day [ADDRESS_601736] visit (Day 30 ± 4 days) for evaluation of TEAEs. 
Height and  weight will be measured , and BMI calculated , at the Screening  Visit. Weight only 
will be measured on D ay -2, and Day 14 (±3 day s), or ET.   
Refer to the protocol- specific MOP for fu rther details. The findings of each examination will be 
recorded on the subject’s source documents and eCRF. Any new findings on examination or 
worsening of existing conditions after dosing are to be reported as TEAEs.  
 Vital Signs  
VS include resting ( measured after supi[INVESTIGATOR_1919] 5 min ) systolic blood pressure (SBP) and 
diastolic BP (DBP), heart rate (HR), respi[INVESTIGATOR_697] (RR) and oral temperature (T). VS will be 
measured at the Screening  Visit, on Day -2, on Day -1, on Day 1 ( within 0.5 h [30 min] before 
dosing and at 0.5 h ±5 min, 1 h ±5 min , 4 h ±10 min , and 16 h ±15 min  after dosing); on Day 2 
(at 24 h ±1 h and 36 h ± 1 h after dosing); on Day 3 (at 48 h ±1 h and 60 h ± 1 h after dosing); 
and on Day 14 ( ± 3 day s), or ET.  Normal references ranges are shown in  Appendix B, Table 2 , 
and exceptions for enrollment in Section  5.1, Inclusion Criterion #2. 
VS that are considered aberrant due to an error in measurement may be repeated. At S creening 
and after dosing, an abnormal VS  measurement may be repeated up to two more times  at rest, 
within [ADDRESS_601737] will be excluded (if at Screening  Visit) or 
the event reported  as a TE AE and graded for severity per Appendix B, Table 2  (if after dosing). 
If the second measurement is normal, a third measurement will be taken  at least  after [ADDRESS_601738] is eligible (if at Screening  Visit) or there 
is no TEAE (if after dosing); if it is abnormal, the subject will be excluded (if at Screening Visit) 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601739] assessed grade (between first and third measurements) 
and graded for severity per  Appendix B,  Table 2  (if after dosing).  
 12-lead Standard Electrocardiogram  (ECG) 
Single 12- lead standard ECG and  10-sec rhythm strip will be obtained at the Screening  Visit, on 
Day -2, at 24 ±1  h and 36 ± 1  h (Day 2) and 48 h ±1  h and 60 h ±1  h (Day 3) after dosing, and on 
Day 14 (± 3 days), or ET.  
Triplicate  12-lead standard ECGs will be obtained over a period of 5 minutes on Day -1 (at the 
same 4 timepoints as projected to be taken on Day 1), and on Day 1 pre-dose (within 30 min) and 
at 1 h ±5 min , 4 h ±10 min and 16 h ± [ADDRESS_601740] 5 min. The ECGs will be reviewed by [CONTACT_978] [INVESTIGATOR_1660] a designated clinician (listed on FDA Form 1572). ECGs will be analyzed for PR, QRS and QT  interva ls, ventricular rate (based on RR intervals) , and for 
morphological abnormalities. The QT interval will be corrected by [CONTACT_469414] (QTcF) formula , recorded  and analyzed . To be eligible for participation, the QTcF interval must be 
within protocol reference range criteria at Screening and Day -[ADDRESS_601741] would not be eligible to receive study drug and should be 
withdrawn and replaced.  ECG PR  and QTcF intervals after dosing will be reported as TE AEs if 
they meet toxicity grading criteria (S ee Ap pendix B, Table 4).  If a question regarding ECG 
interpretation  arises , the study investigators will have the ECG reviewed by a cardiologist. 
 Spi[INVESTIGATOR_469361]1 and FEV1/FVC at Screening. A subject will be eligible if predicted FEV1  is ≥ 80% and FEV1/FVC  is > 70 %. 
8.2 Laboratory Evaluations  
Venipuncture schedule and blood volumes are shown in Appendix A  and Appendix C, 
respectively .  
 Clinical Laboratory Evaluations (Hematology, Coagulation, Chemistry, and 
Urinalysis) . 
Blood and urine samples for clinical laboratory tests will be collected at the Screening  Visit and 
on Day  -2 to determine eligibility , and on Day 1, pre-dose, to determine (B aseline) . Clinical 
laboratory tests will also be collected on Day 2  (24 h  ± 1 h after dosing), Day 3 (48 h ± 1 h after 
dosing), and on Day 14 ( ± 3 day s) or ET . Subjects must be fasting at least for 6 h before any 
blood draw for clinical laboratory assessment s. These tests will include: 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     65 • HEM: Hgb, Hct, RBC,  platelet count, and WBC count with absolute differential count. 
• COAG: INR with prothrombin time, alpha partial thromboplastin time . 
• CHEM: electrolytes (sodium, potassium, chloride, total carbon dioxide [CO 2]), calcium, 
magnesium, creatinine,  with estimation of GFR  by [CONTACT_91019]-EPI [INVESTIGATOR_10908], blood urea 
nitrogen (BUN), glucose (fasting), total bilirubin, direct bilirubin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), 
total prote in, albumin, TSH, free  T4, and free T3 . 
o The CKD -EPI [INVESTIGATOR_10908], expressed as a single equation, is GFR = 141 × min(Scr/κ, 
1)α × max(Scr /κ, 1) -1.209 × 0.993Age × 1.018 [if female] _ 1.159 [if black], where 
Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is  
-0.329 for females and - 0.411 for males, min indicates the minimum of Scr/κ  or 1, 
and max indicates the maximum of Scr/κ or 1 (Levey et al  2009). 
• UA: Routine dipstick testing of clean- catch urine for blood, protein, and glucose  
o If urine dipstick is abnormal, urine microscopy will be performed. 
Clinical laboratory tests at the Screening Visit and Day  -2 should be in the normal reference 
range with exceptions . (See Section 5.2, Inclusion Criteria  #2 and Appendix B, Table 3 ). 
Laboratory values that are outside the range of eligibility but are thought to be due to an acute 
condition or due to collection or laboratory error may be repeated once, preferably within [ADDRESS_601742] is available.   
Laboratory values will be transferred to  Advantage eClinical®.  
Abnormal safety laboratory values after dosing will be graded for severity per Appendix B, 
Table [ADDRESS_601743] be negative for study eligibility . In cases where a false- positive result is 
suspected, confirmatory testing (e.g., polymerase chain r eaction)  may be performed . 
 Pregnancy Testing  
In all women, a serum β -HCG pregnancy test  will be done at the Screening Visit. A urine 
pregnancy test will be done upon check in on Da y -[ADDRESS_601744] be negative for dosing 
with study drug.   
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     [ADDRESS_601745] the 
presence of  amphetamines, cocaine, barbiturates, benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_2573], 
methylenedioxymethamphetamine ( MDMA ), methadone, marijuana (THC) , methamphetamine, 
tricyclic antidepressants ( TCA s), and phencyclidine. R esult s must be negative for study 
eligibility. Urine creatinine will be measured as part of the profile to assess quality of collected 
sample.  
 Alcohol Breathalyzer T est 
A breathalyzer test for alcohol will be performed at Screening and Check -in (Day - 2). Results 
must be negative for study eligibility . 
 Urine Cotinine T esting  
Detection of urine cotinine, for recent tobacco products consumption, will be performed at the Screening Visit, and on Day -2. A positive urine cotinine at screening is allowed but r esult s must 
be negative on Day -2 for study eligibility  for enrollment. 
 Exploratory Biomarkers for Renal Injury 
The following tests will be performed on indicated days for exploratory purposes, not to determine eligibility:  
 Serum Cystatin  C 
The test will be performed in enrolled subjects on Day -2, pre-dose on Day 1 (B aseline), Day 3 
(at 48 h ± 1 h after start of dosing), Day 14 ( ± 3 day s), and Day 30 (± 4 days), or ET .  
 Urinary KIM-[ADDRESS_601746] will be performed in enrolled subjects on Day -2, pre-dose on Day 1 (B aseline), Day 3 
(at 48 h ±1 h after start of dosing ), Day 14 ( ± 3 day s), and Day 30 (± 4 days), or ET .  
8.3 Bronchoscopy with Bronchoalveolar Lavage  
Bronchoscopy with bronchoalveolar lavage is performed to obtain fluid samples from a lung 
segment following dosing with apramycin to measure the accumulation of the drug in the lung. 
The procedure will be performed in the Pulmonology Department of the UTMC, which is accredited to perform this procedure, according to established SOPs by [CONTACT_469415] 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     67 pulmonologists and support staff. The procedure will be done in eligible and enrolled subjects 
who were assigned to cohorts T1 -T5, at the following nominal timepoints : 0.5 h ±5 min (T1), 2h 
±5 min  (T2), 4 h ± 10 min (T3), 8 h ± 15 min (T4) and 24 h (nominal) ±1 h (T5) after the start of 
apramycin infusion. (The exact timing of T5 will be determined after review of BAL apramycin 
concentrations in cohorts T1 to T4.) Subjects in each cohort will have only one procedure done 
during the study.  
Subjects , who had previously been informed of the procedure and provided informed consent, 
will be taken to the bronchoscopy suites by [CONTACT_469410], will review the procedure with the 
operator and confirm understanding prior to the procedure. The subject will be monitored during 
the procedure by [CONTACT_385363], pulse oximetry and will rec eive oxygen as needed. Sedation or light 
anesthesi a will be induced by [CONTACT_469416]. The procedure will be 
performed according to standard protocol and a study- specific protocol ( SSP) for the collection 
of BAL samples for PK analysis. BAL samples will be stored on ice and then transferred into test tubes to the CTU research lab for measurement of total and differential cell counts and for 
centrifugation and processing  into BAL supernatant (containing ELF ) and BAL pellet 
(containing AM ) samples . After the procedure, the subject will be observed in the recovery room 
for side effects and will be released by [CONTACT_941] p ulmonologist to the care of the CTU staff  when 
stable. The subject will continue to be monitored closely until dis charge from the CTU.  
Procedure records will be obtained by [CONTACT_469417] .   
8.4 Ear Examination and Oto acoustic Testing  
Ear exams and otoacoustic tests will be performed by [CONTACT_469418] . The following tests will be 
performed  at the indicated study visits . These tests may be performed at the screening visit,  or at 
a second screening visit due to time restrictions on the initial visit.  
• Ear otoscopy, Valsalva test, Tympanometry and S tapedial R eflexes  (Screening visit). 
• Ear otoscopy only (D ay -2 [or Day -4 or Day -3 if needed], D ay 3 (+2 days), Day 14 
(± 3 days) and Day 30 (± 4 days), or ET).  
• Audiometry. 
o Pure tone audiometry at standard frequencies , 0.5 to  8 kHz ( Screening  visit).  
o Pure tone audiometry at standard (0.5 to  8 kHz) and higher frequencies ( Day -2 [or 
Day -4 or Day - 3 if needed],  Day 3  (+2 days), Day 14 (± 3 days), and Day 30 
(± 4 days) , or ET.  
• Distortion product otoacoustic emissions  (DPOAEs ) at Screening Visit, and on Day -2 
[or Day -4 or Day - 3 if needed] , Day 3 (+2 days), Day 14 (±  3 days), and Day 30 
(± 4 days), or ET. 
Note  1: On Day 3, ear otoscopy, audiometry and DPOAEs can be done at any time. 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     68 Note 2 : If otoacoustic assessments could not be performed on Day 3, the subject will be 
discharged from the CTU on Day 3 after all other assessments are completed. Otoacoustic 
assessments will be completed up to Day 3 (+2 days) as outpatient. 
Audiology records will be obtained by [CONTACT_469419].   
8.5 Bioanalytical Assays for Pharmacokinetics (PK)  
The following LC -MS/MS methods will be validated before subject enrollment starts for 
determinatio n of concentration of apramycin in plasma and bronchoalveolar lavage (BAL) 
samples : Total and Free apramycin in plasma, total apramycin in BAL supernatant  (BAL SUP, 
containing ELF ), and total apramycin in BAL pellet (BAL AM ). In addition, a validated LC -
MS/MS method will be used for the measurement of urea in plasma and BAL SUP .  
 Assay for Total Apramycin  in Plasma  
A single dose of apramycin will be administered by 30 (± 5) min IV infusion.  Blood (plasma) 
samples for assay of total apramycin  concentration and estimate of PK  parameters  will be 
collected at the following study days and timepoints : On Day 1  within 30 min before  dosing, and 
0.5 h (±5 min , immediately at end of infusion), 1 h (± 5 min), 2 h (± 5 min), 4 h (±10 min), 8 h 
(±15 min), and 16 h (±15 min) after dosing; on Day 2 at 24 h (±  1 h) and 36 h (± 1 h) after 
dosing; and on Day 3 at 48 h ( ± 1 h) and 60 h ( ± 1 h) after dosing, or ET  if occurs within 24 h of 
dosing.  
Plasma samples for total apramycin concentration should be collected within 5 min of the 
corresponding BAL procedure at 0.5 h ( ± 5 min , immediately after the end of infusion), 2 h  
(± 5 min ), 4 h ( ± 10 min ), 8 h ( ± 15 min ) and 24 h ( ± 1 h) after the start  of the infusion. If BAL is 
delayed, blood (plasma) for apramycin will be collected at the nominal timepoint (including windows) and a second sample will be collected within [ADDRESS_601747]  ECG 
timepoint and VS assessment . 
Sample collections will be scheduled for the nominal time  point and actual collection times 
recorded  in source documents. If bronchoscopy/BAL is delayed, an additional sample for plasma 
apramycin assay should be collected wi thin [ADDRESS_601748] BAL sample, to be 
used for the calculation of Lung PK / Plasma PK ratios.  
 Protein Binding Test for Apramycin in Plasma 
Protein binding of apramycin in plasma will be measured at the following timepoints : 0.5 h  
(± 5 min; immediately at the end of infusion), and 36 h (± 1 h) after the start of the infusion. The 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     69 assay will be performed in plasma PK aliquots collected at the matching time points  as described 
in Section  8.5.1. A s eparate blood collection is not required. 
 Assays for Total Apramycin in Bronchoalveolar Lavage C omponents ( ELF and 
AM)  
During bronchoscopy with bronchoalveolar lavage (BAL), samples will be obtained at the 
following timepoints overall during the study: 0.5 h ( ± 5 min ), 2 h ( ± 5 min ), 4 h (± 10 min), 8 h 
(±15) min and 24 h (± 1 h) a fter the start of the infusion. Each subject will have bronchoscopy 
with BAL at one timepoint only. At each time point, BAL samples will be collected from 4 subjects  assigned to one of the cohort s T1-T5. Each BAL collection will be centrifuged for the 
separation of the supernatant ( BAL SUP  containing ELF ) and the pellet  (BAL AM ) components, 
and total apramycin will be measured in BAL  SUP  and BAL AM. Due to dilution during BAL, 
the concentration of apramycin in ELF  will be corrected using the urea method (Tenero 2013; 
Gottfried 2017; Rizk 2018). Formulae for the calculations will be provided in the SAP. 
 Plasma and BAL Urea assay  
Urea will be assayed i n plasma  samples collected at baseline (as part of the total apramycin 
plasma PK ) and at 0.5 h (± 5 min, immediately after the end of infusion ), 2 h (± 5 min), 4 h 
(± 10 min) , 8 h (± 15 min) and 24 h (± 1 h) after the start of the infusion), and in BAL SUP  
samples corresponding to plasma PK timepoints. If BAL is delayed and a second plasma sample is collected within [ADDRESS_601749] BAL sample, plasma urea will be measured only in the second sample.   
 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_469362], Handling, and Storage 
Details regarding the specimen preparation, handling, and storage of bioanalytical samples for the measurement of plasma total and free apramycin, total apramycin in BAL SUP ( containing 
ELF) and BAL AM , plasma urea, and urea in BAL SUP ( ELF) will be described in the protocol-
specific MOP.  
Blood samples and BAL samples l eft after all routine clinical laboratory testing and 
pharmacokinetic assays are completed will not be stored indefinitely or used for purposes other than those described  but will be disposed of per DMID (sponsor) guidance . No genetic testing 
will be done on collected blood samples and BAL samples.  
 Specimen Shipment  
Specimen shipment will occur at intervals during th e trial following all applicable International 
Air Transport Association (IATA) requirements and according to the specifics for storage 
DMID Protocol 20-0012   Version 5.0 
Apramycin  10 July 2023  
DMID/NIAID/NIH 
CONFIDENTIAL     70 temperature and documentation as detailed in the central clinical laboratory manual and protocol-
specific MOP , as appropriate.  
All specimens for clinical screening and safety laboratory evaluations will be transported from the CTU  to the local clinical laboratory.  
Plasma and Bronchoalveolar BAL SUP (containing E LF) and BAL AM samples for 
bioanalytical assays  will be shipped from the CTU  to DMID -CMS at:  
Fisher BioServices  
c/o DMID Clinical Materials Services (CMS ) 
[ADDRESS_601750] 
Germantown, MD [ZIP_CODE] 
Phone: [PHONE_6136]  
Fax: [PHONE_6137] 
Email: [EMAIL_5798]   
Plasma and Bronchoalveolar BAL SUP (containing E LF) and AM samples will then be provided 
by [CONTACT_122830]- CMS to the bioanalytical lab, KCAS Inc., at:  
Test Materials Management (TMM)  
KCAS Bioanalytical and Biomarker Services  
[ADDRESS_601751] Olathe, KS, [ZIP_CODE] 
Telephone: [PHONE_9816] 
Fax: [PHONE_9817] 
Email: [EMAIL_9000]  
Further information will be provided in the study- specific MOP.   
 
 Long- term Storage of Plasma and BAL (ELF and AM)  PK Samples  
Any residual plasma and BAL samples ( BAL SUP [ ELF] and BAL AM) collected for the 
measurement of total apramycin concentration may be stored at the DMID CMS long- term and 
used for future exploratory research if collected from subjects who consented to its use for this 
purpose. (See Section 14.8)  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  71 9 ASSESSMENT OF SAFETY  
Regulatory requirements including FDA regulations and  ICH Guidelines for GCP set forth safety 
monitoring and reporting responsibilities of sponsors and investigators to ensure the safety and protection of human subjects participating in clinical trials.  
Responsibilities : 
Investigators participating in this clinical trial are responsible for and will: 
• Evaluate subject safety including assessment of treatment -emergent adverse events 
(TEAEs ) for seriousness, severity, and causality (relatedness to study drug). 
• Notify DMID of treatment- emergent serious AEs ( SAEs ) within 24 h of site awareness. 
• Provide detailed written reports, including necessary documentation requested by [CONTACT_469420]/EC, promptly following immediate initial reports . 
• Inform the IRB/EC of SAEs and TEAEs as requi red by [CONTACT_82089] . 
9.1 Specification of Safety Parameters  
Safety will be assessed by [CONTACT_469421], frequency, causality , and severity of: 
1. Treatment -emergent AEs and SAEs occurring from time of dosing through Final Visit 
(Day 30 ± 4 days), or ET . 
2. Clinical laboratory TEAEs occurring from time of first dose through Day 14 (± 3 days),  
or ET . 
3. 12-lead standard ECGs performed in the 24-h period after dosing, on Day 3, and Day 14  (± 3 days), or ET. 
4. Audiology (Ear examination and otoacoustic testing) TEAEs at Day  3 (+ 2  days), Day  14 
(± 3 days) and Day 30 (± 4 days), or ET .  
9.[ADDRESS_601752]. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with use of the product, 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  72 and are described as treatment -emergent AEs (TEAEs) . The occurrence of a TEAE may come to 
the attention of study personnel during study visits and interviews, or by a subject presenting for medical care.  
The FDA defines an AE as any untoward medical occurrence associated with the use of a drug in 
humans, whether it is considered drug- related or not.  
Any systemic medical condition, VS and ECG measurement, and cli nical safety lab test value 
that is present on Day 1 prior to dosing will be considered a baseline finding for the purpose of data analysis. For ear and otoacoustic testing, baseline comprises assessments performed on  Day -2. However, if the condition increases in severity or frequency after IM P administration at 
any time during the trial, it will be recorded as a TE AE. 
Any medical condition that is reported after screening but before study drug administration will be evaluated  and reported as MH update.  
All TEAEs will be graded for severity according to  Appendix B, Table 2 , Table 3 , and Table 4 
and for relationship to the study drug.  
 Severity of Events  
Intensity of TE AEs will be graded as follows, unless otherwise specified in Appendix B:  
Mild:  Require minimal or no treatment; do not interfere with the subject’s daily activities.  
Moderate:  Result in a low level of inconvenience or concern with therapeutic measures; may 
cause some interference with functioning. 
Severe:  Interrupt a subject’s usual daily activity and may require systemic drug therapy or other 
treatment ; are usually incapacitating.  
 Relationship to Study Products  
TEAEs and treatment- emergent SAEs will be assessed by [CONTACT_469422], using the following two terms. In a clinical trial , the study drug 
must always be suspect.   
• Related:  There is a reasonable possibility that the study drug caused the treatment-
emergent AE /SAE . 
• Not Related : There is not a reasonable possibility that the  study drug caused the 
treatment -emergent AE/SAE . 
The investigator will provide an assessment of association or relationship of each treatment -
emergent AE/SAE  to the study drug based on: 
• Temporal relationship of the TEAE/SAE to study drug dosing. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  73 • Whether an alternative etiology has been identified. 
• Biological plausibility . 
• Existing therapy and/or ConMeds. 
 Reporting Adverse Events  
TEAEs will be captured on the appropriate subject’s source document and eCRF. Information collected for TEAEs includes event descri ption, time of onset, investigator assessment of 
severity  and relationship to the study drug, date of resolution of the event, seriousness, and 
outcome. 
All TEAEs will be documented from the time of study drug dosing through the time of last 
assessment (e. g., Day 14 ± 3 days for clinical safety labs  and ECGs ) or Final Visit (Day 30 ± 
4 days), or ET. All TEAEs including abnormal safety laboratory test results will be followed to 
resolution or until considered stable in the clinical judgment of the study investigator. Evaluation of TEAEs may require unscheduled visits and clinical and laboratory investigations, according to the clinical judgment of the Site PI a nd study physicians. 
 Serious Adverse Events  
An SAE is any treatment -emergent AE that meets at least one of the following criteria:  
• Death . 
• Life-threatening AE*. 
• Inpatient hospi[INVESTIGATOR_1081]. 
• Persistent or significant disability or incapacity, or substantial disruption of the ability to 
conduct normal life function. 
• Congenital anomaly/birth defect. 
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bron chospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
*A TEAE is considered “life-threatening” if, in the view of either the investigator or DMID , its 
occurrence places the subject at immediate risk of death. It does not include a TEAE that, had it 
occurred in a more severe form, might have caused death. 
SAEs will be: 
• Assessed for severity and relationship to study product and alternate etiology by [CONTACT_469423] (listed on FDA Form 1572). 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  74 • Recorded on the appropriate SAE data collection form and eCRF. 
• Followed through resolution. 
• Reviewed and evaluated by [CONTACT_4484] (periodic review unless related ), DMID, and the 
IRB. 
 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  
A licensed study clinician (listed on FDA Form 1572) will determin e seriousness, severity, and 
causality  of abnormal laboratory values; provide a medical evaluation of TEAEs;  and classify 
TEAEs  based upon medical judgment. 
Abnormal laboratory values or clinical findings for all enrolled subjects after dosing will be 
assessed using the toxicity scales in  Appendix B . Out of range values and findings noted at 
screening or baseline, but allowable for enrollment and dosing if within Grade 1 , will only be 
considered TEAEs if their severity increases to Grade 2  or higher. For abnormalities noted from 
the time of study drug dosing, any Grade 1 or higher laboratory abnormality listed on the toxicity Table 3  in Appendix B will be entered in the database as a TE AE. Safety laborat ory results that 
are reported as TEAEs will be evaluated by [CONTACT_469424] (CS) or 
not clinically significant (NCS).  Abnormal laboratory values , performed as part of HEM , 
COAG, CHEM , or UA but  not listed in this  toxicity table will be evaluated by [CONTACT_469425], recorded in the source document and , if clinically significant,  considered TEAEs and 
graded according to the criteria in Section 9.2.1. 
Protocol- specific laboratory normal range values are included in  the study- specific MOP and 
toxicity grades for evaluation of TEAEs are included in Appendix B, Table 3 . 
Gross blood in urine that is confirmed due to menses  is not a TEAE  (but is for all other reasons). 
9.3 Reporting Procedures  
 Serious Adverse Events  
SAEs will be followed until resolution even if this extends beyond the study-reporting period.  
Resolution of an S AE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
 
All SAEs will be : 
• Recorded on the appropriate SAE  report form and sent to DMID  Pharmacovigilance 
Group ( PVG). 
• Entered  into the appropriate subject source document and eCRF in Advantage eClinical® 
• Reported to the IRB. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  75 • Reviewed and followed to resolution or stability by [CONTACT_469426] (listed 
on FDA Form 1572). 
• Collected on each subject until Day 30 ± 4 days ( Final  Visit), or ET Visit . 
Any TEAE that meets a protocol -defined serious criterion will be submitted immediately (within 
24 h of site awareness) on an SAE report form to DMID PVG:  
DMID P harmacovigilance G roup  
Clinical Research Operations and Management Support (CROMS ) 
[ADDRESS_601753] ive, Suite 650 
Bethesda, MD [ZIP_CODE], [LOCATION_003] 
SAE Hot Line: 1 -[PHONE_889] (US) or [PHONE_2619] (outside US) 
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393]  
In addition to the SAE report form, selected SAE data fields will also be entered into Advantage 
eClinical®. Please see the  protocol-specific MOP for details regarding this procedure. 
Other supporting documentation of the SAE may be requested by [CONTACT_469427]. 
The DMID Medical Monitor ( MM) and DMID CPM  will be notified of the SAE by [CONTACT_469428]. The DMID MM will review and assess the SAE for regulatory reporting and potential 
impact on subject safety and protocol conduct. 
At any time after completion of the trial, if the S ite PI  [INVESTIGATOR_29353]-inve stigator becomes 
aware of an SAE that is suspected to be related to study drug, the S ite PI  [INVESTIGATOR_29353]-
investigator will report the event to the DMID PVG. 
 Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the investigator, DMID, the Investigational New Drug (IND) 
sponsor, will report any suspected TEAE  that is both serious and unexpected. DMID will report 
an AE  as a suspected AE  only if there is evidence to suggest a causal relationship between the 
drug and the TEAE . DMID will notify FDA and all participating investigators (i.e., all 
investigators to whom DMID  is providing drug under its IND(s) or under any PI ’s IND(s)) in an 
IND safety report of potential serious risks from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar days after DMID  determines that the information 
qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify FDA of any unexpected fatal TEAE or suspected life -threateni ng TEAE  as soon as possible, but in no case 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  76 later than 7 calendar days after DMID ’s initial receipt of the information. Relevant follow up 
information to an IND safety report will be submitted as soon as the information is available. Upon request from FDA, DMID will submit to FDA any additional data or information that the 
agency deems necessary, as soon as possible, but in no case later than [ADDRESS_601754].   
All serious events designated as “not related” to  the study drug will be reported to the FDA at 
least annually in a summary format. 
 Other Adverse Events (if applicable)  
 Reporting of Overdose 
An overdose is defined as a dose greater than the high- dose level evaluated in the trial as 
described in Section 6.3.1 of the protocol. All overdoses will be reported; if the overdose is associated with a TE AE, then the TEAE will also be reported. In the event of an overdose of 
study drug, the investigator will use clinical judgment in treating the overdose and contact [CONTACT_469429]. There is no specific antidote in case of apramycin overdose. The same measures as recommended for other aminoglycosides (treatment cessation, adequate hydration, dialysis, administration of calcium salts for symptoms of neuromuscular blockade) should be considered 
until further clinical data are available for apramycin . The investigator will refer to the relevant 
document(s) for detailed information regarding warnings, precautions, contraindications, TEAEs, 
and other significant data pertaining to apramycin . Such documentation may include but not be 
limited to the IB.  
 Reporting of Pregnancy 
Pregnancies that occur in female s ubjects during the trial will be reported via Advantage 
eClinical® on a p regnancy report f orm. With the subject’s permission , all protocol-required 
venous blood samples will be obtained, and the subject will continue to be followed for safety 
until Day 30 ± 4 days ( Final  Visit). Efforts will be made to follow all pregnancies reported 
during the trial to pregnancy outcome, as described in the protocol- specific MOP (e.g., delivery, 
spontaneous abortion, or therapeutic abortion), pending the subject’s permission.  
A female subject who participates in the trial and becomes pregnant will be asked to inform 
study personnel of a pregnancy occurring 30 days after Final Visit. For all reported pregnancies, 
subjects will be asked to provide pregnancy outcome upon deliver y or pregnancy termination to 
the CTU .  
Serious adverse outcomes of pregnancy affecting the mother and/or fetus or neonate (e.g., spontaneous abortion, congenital anomaly(ies) in fetus or child, late fetal death, or reports of 
adverse drug reactions in a newborn/neonate that is fatal, life-threatening, resulting in persistent 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  77 or significant disability/incapacity or resulting in or prolonging hospi[INVESTIGATOR_059]) will be documented in a SAE form and reported to the CROMS PVG within [ADDRESS_601755]'s source 
document and e CRF . 
9.5 Halting Rules  
 Study Halting Criteria  
Systemic or Lab Criteria:  
• One subject has an SAE that is determined to be related to the study product. OR  
• Two or more subjects experience Grade 2 or higher related TEAE (laboratory or 
systemic) that is coded in the same HLGT per MedDRA classification, and if AE is not resolved within 48 hours through Day 4. Resolution is defined as return to a baseline status. Note: If the event starts on Day 4, the review period will be extended to Day 5. 
Note: VS abnormalities will be considered part of a systemic disorder or an organ-
specific condition, as described in Appendix B: Adverse Events Toxicity Grading 
Criteria , in order to be included among the Study Halting Criteria. 
Ototoxicity Criteria: 
• Two or more subjects experience Grade 2 or higher ototoxic change of pure-tone audiometry through Day 30 ± 4 days that is confirmed by [CONTACT_15013], generally within 
24 h, and assessed as related to I MP.  
• A single subject experiences significant ototoxic change in DEOAE s, characterized by 
[CONTACT_469430] 70% at three consecutive frequencies where responses were previously obtained, through Day 30 (± 4 days) and is confirmed by [CONTACT_15013], generally within 24 h:  
If the predefined criteria for the halting rules are met, the SMC will review the study data and 
provide guidance on how to proceed
. 
A halted study will resume upon recommendation by [CONTACT_1034] (DMID).  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  78 9.6 Safety Oversight  
 Safety Monitoring Committee (SMC)  
Safety oversight will be conducted by a SMC, which is an independent group of experts that 
monitors subject safety and advises DMID. SMC members will be separate and independent of 
study personnel participating in th e trial and will not have scientific, financial , or other conflicts 
of interest related to th e trial. The SMC will consist of  a minimum of three members with 
appropriate expertise to contribute to the interpretation of the data from the trial.  
The SMC will meet as follows: 
• Organizational meeting ( before  study initiation ). 
• Ad hoc  meeting . 
o When study halting criteria are met . 
o At the request of DMID to review a potential safety concern identified by [CONTACT_469431]  [INVESTIGATOR_469363] . 
• Scheduled  meeting . 
o The SMC will review cumulative, interim safety data when available after completion of all subjects in cohorts T1 to T4 . 
o The SMC will review final safety data after completion of all subjects in all cohorts, 
including T5, when available after database lock .  
Procedures for SMC reviews/meetings will be defined in the SMC charter. The SMC will review 
safety  data and provide recommendations to DMID, NIAID on resumption or stoppi[INVESTIGATOR_31081] a 
temporary halted trial, and safety monitoring in future clinical trials with apramycin .  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601756] protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality and meet DMID , GCP/ICH , and regulatory guidelines, when appropriate . Site visits may be 
conducted by [CONTACT_469432], subjects’ medical records, and eCRFs in accordance with ICH guidelines, GCP, and the 
respective local and national government regulations and guideline s. 
The investigator will permit authorized representatives of DMID and the respective local and 
national health authorities to inspect facilities and records relevant to th e trial, if needed. 
A separate monitoring plan developed by [CONTACT_469433]- specific items to be 
monitored. 
Site visits will be made at standard intervals defined by [CONTACT_469434]. Monitoring visits will include, but not be limited to , review of regulatory 
files, account ability records, subjects ’ source documents, eCRFs, ICFs , clinical and laboratory 
reports, and protocol and GCP compliance. Site monitors will have access to the CTU , study 
personnel, and all study documentation according to the DMID-approved site monitoring plan. Study monitors will meet with the S ite PI  [INVESTIGATOR_469364]. 
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  80 11 STATISTICAL CONSIDERATIONS  
11.1 Study Hypotheses  
The objectives of the study are to obtain lung and plasma PK  and s afety data for apramycin. 
There are no formal hypotheses being tested in this Phase 1 trial. 
11.2 Sample Size Considerations  
Enrollment of 20 subjects assigned into 5 cohorts, T1- T5 (T5 will undergo bronchoscopy with 
BAL after completion of cohorts at the 24 h nominal timepoint, with the optimum timepoint to 
be selected after completion of T1 -T4), with [ADDRESS_601757] of the trial. A scheduled SMC meeting 
will be held after all subjects in timepoint cohorts T1 to T4 complete the trial to review safety 
data. If criteria for halting the trial (as listed in Section 9.5.1) are met, an ad hoc  SMC meeting 
will be held to review all available safety data and to make recommendations about the dosing of 
all further subjects in the trial.  A statistician may present data in a closed session of an SMC  
meeting . If group T5 will enroll, a final SMC mee ting will be held to review all data and advise 
on safety monitoring in future clinical trials of apramycin.  
11.4 Final Analysis Plan  
The ICH Guidance E9 (Statistical Principles for Clinical Trials) will be followed for all statistical 
content. S ummaries of fre quencies and percentages will be presented  for categorical data, and  
summary statistics such as  minimum, median, mean, SD , and maximum values will be presented 
for continuous data . Details of plasma and BAL SUP (containing ELF ) and BAL AM apramycin 
PK, lung PK/ plasma apramycin  exposure ratios, safety , ECG interval measurements  (QT, PR, 
QRS , and HR ), and ECG morphology data analyses and  presentation s will be described in the 
Statistical Analysis Plan (SAP) and accompanying Tables, Listings , and Figures (TLF) 
templates. The SAP for PK and safety data will be prepared and finalized by [CONTACT_941] S DCC before 
analysis of the PK data after completion of cohort s T1-T4. A final analysis containing safety data 
and PK data from  cohorts T1-T4 and cohort T5, if enrolled, will be performed by [CONTACT_941] S DCC after 
final data lock  and included in the clinical study report (CSR). Any change from originally 
planned statistical analyses will be reported in the CSR.    
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  81 
 Analysis Populations 
The safety population will include all subjects who received any amount of the IMP. The per protocol safety population subset will include all subjects who received a  complete dose of study 
drug ( apramycin ) and analyzed as treated.  
The lu ng PK population will consist of all the subjects who received a complete dose of 
apramycin , underwent BAL at the assigned sampling timepoint with BAL return volume 
adequate for analysis  and have at least one quantifiable drug concentrations separately for BAL 
SUP (contain ing E LF) and BAL AM.  
The plasma PK analysis population will consist of all subjects who received a complete dose of 
apramycin  and have at least one quantifiable post-dosing plasma drug concentration measured.  
The PK analysis subset will be based on the lung and plasma PK population, which includes all 
subjects who completed the lung PK and plasma PK part of the trial without any protocol 
violations that would likely affect the PK results and who have evaluable plasma PK and  BAL 
PK concentration data for apramycin  from wh ich at least a subset of the designated PK 
parameters can be determined. If any subjects are found to be noncompliant with respect to 
dosing or have incomplete data, a decision to include them in the analysis will be made on a 
case-by- case basis.  
 Demographics and Baseline Characteristics  
Subject demographics and baseline characteristics will be summari zed. The number of subjects 
who enroll in the trial, and the number and percentage of subjects who complete each assessment , will be presented. The percentage of subjects who withdraw from the trial or 
discontinue the study drug, and reason s for withdrawal or discontinuation, will be summarized.  
 Safety Analysis 
 Adverse and Serious Adverse Events  
TEAEs will be coded using the latest version of the Medical Dictionary for Regulatory 
Activities® (MedDRA). All AEs occur ring after study drug dosing will be summarized using 
frequency counts and percentages.  The following summaries will be presented for treatment-
emergent AEs and SAEs:  
• Overall (i.e., regardless of severity or relationship to treatment). 
• By [CONTACT_86953] (mild, moderate, or severe). 
• By [CONTACT_469435]. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  82 • By [CONTACT_92255] (system organ class [SOC], higher level group term 
[HLGT ] and preferred term [PT]). 
Unless otherwise specified, at each level of subject summarization in reporting the incidence of 
TEAEs, a subject will be co unted once if the subject reported one or more TEAEs . If more than 
one occurrence of a TEAE is reported, the TE AE of the worst severity or the worst- case 
relationship assessment will be summarized.  
 Additional Safety Analyses  
Descriptive summary statistics  (mean, SD , median, minimum, and maximum) for clinical 
laboratory data, 12- lead standard  ECG parameters , and VS  at admission and each applicable 
post-dosing visit, including changes from baseline values, will be calculated. Baseline values 
will be the last values recorded before administration of study drug. For change -from -baseline 
summaries, subjects with an undefined change from baseline, due to missing data, will be 
excluded. Clinical significance of abnormalities will be  indicated in the listings.  
 PK Analysis  
PK parameters will be estimated for total plasma apramycin , and for ELF and AM total 
apramycin by [CONTACT_469436] (NCA) methods using Phoenix® WinNonlin® version 
8.0 or higher.  
 Plasma PK parameters:  
When evaluable, estimated plasma PK parameters will include: 
• AUC (0-∞): Area under the concentration time- curve from time zero to infinity .  
• AUC (0-t): Area under the concentration time- curve from time zero to time t. 
• AUC (0-24): Area under the concentration time-curve from time zero to 24 h. 
• Cmax: Maximum observed concentration. 
• Tmax: Time of maximum observed concentration. 
• Ke: Elimination rate constant.  
• t1/2: Terminal elimination half -life. 
• CL T: Total  clearance. 
• Vd: Volume of distribution . 
Other PK parameters may be calculated, as appropriate.  
The free portion (fu, % unbound) of plasma apramycin will be calculated from the ratio of free to 
total apramycin concentration in plasma PK samples obtained at 0.5 h (± 5 min, immediately 
after the end of infusion) and 36 h (± 1 h) after the start  of infusion. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  83 
 Bronchoalveolar ELF and AM PK parameters:  
When evaluable, estimated PK parameters from BAL ELF and BAL AM will include: 
• Cmax: Maximum observed concentration.  
• AUC (0-24): Area under the concentration time-curve from time zero to 24 h.  
• AUC (0-t): Area under the concentration time- curve from time zero to the last 
concentration . above the lower limit of quantitation .  
• AUC (0-∞): Area under the concentration time- curve from time zero to infinity . 
• Tmax: Time of maximum observed concentration.  
• t½: Terminal elimination half -life. 
The concentrati on of apramycin in ELF  will be calculated using the urea method (Tenero 2013, 
Gottfried 2017, Rizk 2018). The formulae for calculating ELF  concentration will be provided in 
the SAP .  
 Ratio of exposure parameters of Lung PK to Plasma PK: 
When evaluable, the following exposure ratios of total apramycin will be calculated:  
• ratio of C max in ELF over C max in plasma . 
• ratio of C max in AM over C max in plasma . 
• ratio of AUC (0-24), AUC (0-t) and AUC (0-∞)  in ELF over AUC (0-24), AUC (0-t) and AUC (0-∞)  in 
plasma . 
• ratio of AUC (0-24), AUC (0-t) and AUC (0-∞) in AM over AUC (0-24), AUC (0-t) and AUC (0-∞)  in 
plasma . 
The results of PK parameters for apramycin in plasma , ELF, AM, and the exposure (C max and 
AUC ) ratios of lung/plasma ( total and free) will be listed by [CONTACT_1130], and summarized with 
descriptive statistics including n, mean , SD, coefficient of variation , median, minimum, 
maximum, geometric mean and geometric SD  at each timepoint.  
Graphical presentations of concentration vs. time profiles will be provided for apramycin  and 
will include individual subject and mean concentration profiles. Semi -log concentration profiles 
will be provided for individual subjects. The ratios of lung PK exposure / plasma PK exposure vs time profiles  for total pla sma apramycin  will be presented graphically  for the ELF and AM 
components of BAL samples .  
 Missing Values and Outliers  
All attempts will be made to  collect all data per protocol.  No imputation will be performed for 
missing values. Outliers will not be excluded from the primary analyses. Outliers identified during the PK analysis will be discussed in the analysis report. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  84 
 Analysis of ECG Parameters  
 ECG Analysis and Interpretation  
For replicate ECGs recorded on Day -1 and Day 1, t he ∆∆QTc F, calculated as difference 
between mean change- from -baseline QTc F values at each timepoint on Day 1 after treatment  
with apramycin relative to time -matched ECG recording before dosing in Day -1, will be 
evaluated to quantify the QTcF prolongation. For single ECG recordings after dosing, ∆QTcF , 
will be calculated as difference between mean change- from - baseline QTcF values recorded at 
the pre-dose timepoints on Day -1 and Day 1.  
QTcF corrections w ill be calculated using Fridericia’s  formula:  
• QTcF=QT/RR0.33 
Other endpoints to be evaluated include HR (bpm ), PR (ms ec), QRS (ms ec), and cardiac 
abnormalities (morphologies, rhythm, and conduction).   All statistical analyses and reporting of ECG data will be conducted on the mean of the replicate 
intervals  within a timepoint on Day -1 and Day 1. Descriptive statistics including two -sided 90% 
CI will be generated for observed, change- from -baseline for all ECGs recorded in the study, and 
time-matched change- from -baseline ECG intervals  for replicate ECGs recorded on Day -1 and 
Day 1. 
 Categorical Analyses 
QTcF intervals will be categorized and tabulated for each treatment. The following criteria will 
be used to specif y noteworthy QTcF intervals:  
• QTcF >450 msec  
• QTcF >480 msec  
• QTcF >500 msec  
• QTcF increase  ≥30 msec from baseline  
• QTcF increase ≥ 60 msec from baseline  
Categorical analysis of PR, QRS, and RR intervals will also be performed. The following criteria will be used to specify noteworthy non-QTc intervals (PR, QRS, and RR intervals) and HR :   
• PR change- from -baseline >25% resulting in PR >200 msec  
• QRS change- from -baseline >25% resulting in QRS >120 msec  
• HR change- from -baseline >25% decr ease resulting in HR <50 bpm  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  85 • HR change- from -baseline >25% increase resulting in HR >100 bpm  
The number and percent of subjects in each category will be calculated. Comparisons across timepoints  may be conducted if sufficient counts are observed.  
 Cardiac A bnormalities : 
The morphological waveform analysis of the ECG data at each timepoint will be utilized for the 
summary of new onset cardiac abnormalities for treatment.  Results will be summarized in 
frequency tables with counts and percentages for both number of subjects and number of timepoints.  
 Analysis of Audiology Data 
Descriptive summary statistics (mean, SD, median, minimum, and maximum) of ear audiometric 
and otoa coustic variables at baseline and each applicable post -dosing visit, including changes 
from baseline values, will be calculated. Baseline values will be the last values recorded before 
administration of study drug. For change- from -baseline summaries, subje cts with an undefined 
change from baseline, due to missing data, will be excluded. Clinical significance of 
abnormalities will be indicated in the listings.  
All events occurring after study drug dosing will be summarized using frequency counts and 
percent ages. The following summaries will be presented for each event:  
• Overall (i.e., regardless of severity or relationship to treatment). 
• By [CONTACT_86953] (mild, moderate, or severe).  
Detailed analysis plans will be documented in the SAP.  
Results of the safety and PK evaluations will be reported in the CSR.  
 Interim Report s 
Plasma and BAL (ELF and AM) apramycin concentration and PK data from cohorts T1 to T4 
will be analyzed and summar ized.  
Interim safety data will be presented to the SMC.  
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  86 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS 
The CTU will maintain appropriate medical and/or  research records for th e trial, in compliance 
with ICH E6 GCP, Section 4.9, and regulatory and institutional requirements for the protection 
of confidentiality of subjects. As part of participating in a DMID-sponsored, DMID- affiliated, or 
manufacturer -sponsored trial, the CTU wil l permit authorized representatives of DMID, to 
include The Emmes  Company, LLC (the S DCC ), DynPort Vaccine Company, LLC  (DVC), and 
regulatory agencies to review (and, when required by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study safety and 
progress. 
Forms for use as source documents will be derived from eCRFs and will be provided by [CONTACT_469437] . Additional source data are all information, original records of clinical findin gs, 
observations, or other activities in a clinical trial necessary for the reconstruction and evaluation 
of the trial. Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, pharmacy 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_12192], microfiches, photographic negatives, microfilm or magnetic media, x -rays,  ECG  print-outs, and subject files and records kept at the pharmacy, 
laboratories, and medico- technical departments involved in the trial.  
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601758] acc ess to the CTU , source 
data/documents, and reports for monitoring and auditing by [CONTACT_122830] , and inspection by [CONTACT_21229]. The Site PI [INVESTIGATOR_469365] o n site.  
The S DCC  will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data anomalies will be communicated to the CTU  for clarification  and resolution. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  88 14 ETHICS/PROTECTION OF HUMAN SUBJECTS  
14.[ADDRESS_601759]  
The PI [INVESTIGATOR_71466] e trial is conducted in full conformity with principles of the Belmont 
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 and 56, and ICH E6; 62 Federal Regulations [ZIP_CODE] (1997), if applicable. The PI ’s institution will hold a current 
Federal Wide Assurance (FWA) issued by [CONTACT_469438].  
14.[ADDRESS_601760]  
The CTU will provide for the review and approval of this protocol and associated ICFs  by [CONTACT_153691] /EC listed on the FWA. Any amendments to the protocol or consent materials 
will also be approved before they are used, unless change is for the safety of the subject.  Only 
those IRB members who are independent of the investigators and DMID  will provide an opi[INVESTIGATOR_469366]- related matters. Verification of IRB approval of the protocol and the written ICF will be 
transmitted by [CONTACT_469439]. No deviations 
from or changes to the protocol will be initiated without prior approval of an appropriate amendment unless change is for the safety of the subject. 
14.3 Informed Consent Process  
The written consent document will embod y the elements of informed consent as described in the 
Declaration of Helsinki and will adhere to the ICH Harmonized Tripartite Guideline for G CP. 
Informed consent will be obtained before any protocol-specified procedures or interventions are 
carried out , and  in accordance with 21 CFR 50.25 and 45 CFR 46. Information will be presented 
both orally and in written form. 
An investigator or designee will describe the protocol to potential subjects face- to-face. The ICF 
may be read to the subjects, but, in any event, the investigator shall give the subjects ample 
opportunity to inquire about details of the trial and ask any questions before signing the ICF . 
Study staff will inform subjects that the trial involves research, and explain the purpose of the 
trial, those aspects of the trial that are experimental, any expected benefits, all possible risks (including a statement that the particular treatment or procedure may involve risks to the subject 
or to the embryo or fetus, if the subject is or may become pregnant, that are currently 
unforeseeable), the expected duration of the subject’s participation in the trial, the procedures of the research study, including all invasive procedures, and the probability for assignment to 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601761] (e.g., the I nvestigator) for 
answers to any questions relating to the research project. Information will also include the 
foreseeable circumstances and/or reasons under which the subject’s participation in the trial may 
be terminated. S ubjects will be informed that participation is voluntary and that they are free to 
withdraw from the trial  for any reason at any time without penalty or loss of benefits to which 
the subject is otherwise entitled.  
Neither the investigator, nor the trial staff, will coerce or unduly influence a subject to participate 
or continue to participate in the trial. The extent of the confidentiality of the subjects’ records will be defined, and subjects will be informed that applicable data protection legislation will be 
followed. Subjects will be informed that the monitor(s), auditor(s), IRB, DMID , and regulatory 
authority(ies) will be granted direct access to the su bject’s original medical records for 
verification of clinical trial procedures and/or data without violating the subject’s confidentiality, to the extent permitted by [CONTACT_774], and that, by [CONTACT_2960] a written ICF, the 
subject is authorizing such access. Subjects will be informed that records identifying the subject 
will be kept confidential, and, to the extent permitted by [CONTACT_29695]/or regulations, will not be made publicly available and, if the results of the trial are p ublished, the subject’s 
identity will remain confidential.  
ICFs  will be in a language fully comprehensible to the prospective subjects. Informed consent 
shall be documented us ing a written consent form approved by [CONTACT_469440]. The signature [CONTACT_469450] ’s satisfaction. Each subject’s signed ICF will be kept 
on file by [CONTACT_469441] a uthorities and/or DMID  and 
regulatory compliance persons. The subject will receive a copy of the signed and dated written ICF and any other written information provided to the subjects and will receive copi[INVESTIGATOR_469367].  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  90 14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
Children aged < [ADDRESS_601762] to gender or race. It is expected that race and gender 
distributions in th e trial will approximate the proportion to their numbers within the community.   
Women of childbearing potential will be included but will be repeatedly counseled to use 
effective measures ( Section 5.1) to avoid becoming pregnant from the time of screening until 
Day 30 (± 4 days) (last visit) after the dose of study drug is received because the effect s of the 
study drug on the unborn fetus are not known.    
14.[ADDRESS_601763] party without prior written approval from DMID . This information and data 
will not be used by [CONTACT_941] S ite PI  [INVESTIGATOR_469368]. These restrictions do not apply to: (1) information which becomes publicly available through no fault of the S ite PI  [INVESTIGATOR_29355]; (2) information which is necessary to 
disclose in confidence to an IRB solely for the evaluation of the trial; (3) information which is necessary to disclose in order to provide appropriate medical care to a subject; or (4) study results which may be published as described in Section 16. 
The study monitors or other authorized representatives of DMID  may inspect all documents and 
records required to be maintained by [CONTACT_198991] I nvestigator, including, but not limited to, medical 
records (office, clinic or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in th e trial. The CTU  
will permit access to such records.  
14.[ADDRESS_601764], except as explained below. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601765] be released in order to meet the requirements of the Federal 
Food and Drug Administration (FDA). 
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
information about themselves or their involvement in this research. If any person or agency 
obtains a written consent to receive research information, then the researchers may not use the 
Certificate to withhold that information.   
The Certificate of Confidentiality does not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research 
project regarding matters that must be legally reported , including child and elder abuse, sexual 
abuse, or wanting to harm themselves or others.   
The release of individual private information or specimens for other research will only occur if 
consent was obtained from the individual to whom the information, document, or biospecimen 
pertains, or for the purposes of other research t hat is in compliance with applicable Federal 
regulations governing the protection of human subjects in research. 
14.7 Study Discontinuation  
DMID has the right to terminate th e trial or the CTU’s participation at any time. Reasons for 
terminating the trial may i nclude, but are not limited to: 
• Incidence or severity of TEAEs indicates a potential health hazard . 
• Data recording is inaccurate or incomplete. 
• Investigator does not adhere to the protocol or applicable regulatory guidelines in 
conducting the trial. 
If the trial is discontinued, subjects who have signed the ICF and received the study drug will 
continue to be followed for safety for the duration of the trial. No further study treatments will be 
administered  to other subjects. 
14.8 Future Use of Stored Specimen s 
Blood (plasma) and BAL fluid samples (ELF and AM) will be collected as outlined in the protocol. Subjects will be given a choice during the informed consent process to have their residual linked samples stored indefinitely for future research, have their residual samples de-linked from any subject information and stored indefinitely, or have their residual linked samples 
destroyed at completion of the study. The use of long- term stored linked samples will be 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  92 conducted under the restrictions regarding confidentiality, as outlined in the preceding 
paragraphs. 
Only coded specimens will be sent to the sponsor with the code identifiers maintained by [CONTACT_28824] [INVESTIGATOR_469369], LLC, the NIAID SDCC. Any future research studies will utilize o nly the residual long-term stored specimens from subjects consenting to 
future use, which will be stored at the DMID CAR. Residual, coded samples from the plasma PK 
and BAL ( ELF and AM) PK assays may also be used for future exploratory research.  
Residual clinical samples will be available upon the completion of the study; however, future use 
clinical samples may be requested from DMID and shipped from the DMID C MS at any time.  
The samples will not be sold or used directly for production of any commercial product. No 
human genetic tests will be performed on the samples.  Each sample will be encoded (labeled) 
only with a barcode and a unique tracking number to protect subject confidentiality. 
There are no benefits to subjects in the collection, storage and subsequent use of their specimens 
for future research. Reports about future research done with subjects’ samples will NOT be kept 
in their health records. 
Subjects may be given the option to decide if they want their samples to be used for future 
research or  have their samples destroyed at the end of this trial. The subject’s decision can be 
changed at any time by [CONTACT_154387]. However, if the subject originally consents to future use and subsequently changes his/her decision, any data from a previously collected sample may still be used for this research. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601766] KEEPI[INVESTIGATOR_469370] S ite PI  [INVESTIGATOR_307589], completeness, legibility, and timeliness of 
reported data. All data collection forms wi ll be completed legibl y to ensure accurate 
interpretation of data. Black  or blue ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When 
making changes or corrections, cross out the original entry with a single line, and initial and date 
the change. Do not erase, overwrite, or use correction fluid or tape on the original. 
Data co llection forms will be provided by [CONTACT_941] S DCC  and the CTU will use them to develop the 
CTU’s source documents to record and maintain data for each subject enrolled in the trial. Data 
reported in the eCRF derived from source documents will be consistent with the source documents or the discrepancies will be explained.  
DMID and/or its designee will provide guidance to investigators and other study personnel on making corrections to the data collection forms, source documents and eCRFs. 
15.1 Data Management Responsib ilities 
All source documents and laboratory reports will be reviewed by [CONTACT_328284], who will ensure that they are accurate and complete. TEA Es will be graded, assessed for 
severity and causality, and reviewed by [CONTACT_941] S ite PI [INVESTIGATOR_1660] d esignee.  
Data collection is the responsibility of the clinical trial staff at the CTU under the supervision of 
the S ite PI. During the trial , the investigator will maintain complete and accurate documentation 
for the trial. 
The Emmes Company, LLC will serve as the S DCC  for th e trial, and will be responsible for data 
management, quality review, analysis, and reporting of the study data. 
15.2 Data Capture Methods  
Clinical d ata (including, but not limited to  treatment- emergent  AE/SAE s, ConMeds, MH , PE, 
clinical laboratory data , and ECG data [ ECG intervals  and interpretations ]) will be entered into a 
[ADDRESS_601767] protection and internal quality checks (e.g., automatic range checks ) to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will b e entered 
directly from the source documents by [CONTACT_469442].  
15.[ADDRESS_601768]-
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  94 bronchoscopy records, plasma PK and lung PK (ELF and AM) bioanalytical assay results and 
corrected ELF and AM concentration data, and concentration of urea in plasma , ELF  and AM  at 
each specified timepoint .  
15.4 Timing/Reports  
A final CSR will be prepared after all safety , 12-lead standard ECG , and  plasma and lung PK 
data are available. See Section 9.6.[ADDRESS_601769] elapsed since the formal discontinuation of 
clinical development of the study drug. These documents will be retained for a longer period, 
however, if required by [CONTACT_427]. No records will be destroyed without the written consent of DMID , if applicable. It is DMID ’s responsibility to inform the investigator when 
these documents no longer need to be retained. 
15.[ADDRESS_601770], the investigator, or the CTU  staff. Corrective actions for protocol deviations are to be developed by 
[CONTACT_469443]. 
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3 
5.1 Quality Assurance and Quality Control, Section 5.1.1 5.20 Noncompliance, Sections 5.20.1, and 5.20.2. 
It is the responsibility of the Site PI/study staff to use continuous vigilance to identify and report 
deviations within 5 working days of identification of the protocol deviation, or within 5 working 
days of the scheduled protocol-required activity. All deviations will be promptly reported to 
DMID via S DCC ’s Advantage eClinical
®. 
All protocol deviations, as defined above, will be addressed in subject source documents. A 
completed copy of the DMID Protocol Deviation Form will be maintained in the regulatory f ile, 
as well as in the subject's source document. Protocol deviations will be sent to the local IRB/EC 
per their guidelines. The S ite PI/study staff is responsible for knowing and adhering to their IRB 
requirements.  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601771] submitted for them to the National Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic version of their final, peer- reviewed 
manuscripts upon acceptance for publication, to be made publi cly available no later than 
[ADDRESS_601772] be 
accessible to the public on PubMed Central no later than 12 months after publication. 
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/   
• NIH Office of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm   
As of January 2018, all clinical trials supported by [CONTACT_12242].g ov no later than [ADDRESS_601773] applied for certification of delayed posting. As part of the result posting, 
a copy of this protocol (and its amendments) and a copy of the Statistical Analysis Plan will be posted on ClincialTrials.gov. For thi s trial the responsible party is DMID/NIAID /NIH, which 
will register the trial and post results.   
Refer to:  
• Public Law 110-85, Section 801, Clinical Trial Databases 
• 42CFR11 
• NIH NOT -OD-16-149 
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  96 17 LITERATURE REFERENCES  
1. WHO Model Lists of Essential Medicines, June 2019. (WHO 2019a) Accessed in:   
https://www.who.int/groups/expert- committee -on-selection -and-use-of- essential -
medicines/essential -medicines -lists  
 
2. Critically important antimicrobials for human medicine, 6th revision. Geneva: World Health 
Organization; 2019. Licens e: CC BY- NC-SA 3.0 IGO. (WHO 2019b) Accessed in :  
https://apps.who.int/iris/bitstream/handle/[ZIP_CODE]/312266/9789241515528-eng.pdf 
 
3. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al.; Burden of 
AMR Collaborative Group. Attributable deaths and disability- adjusted life- years caused by 
[CONTACT_469444] -resistant bacteria in the EU and the European Economic Area in 2015: a 
population- level modelling analysis. Lancet Infect Dis. Lancet Infect Dis. 2019;19(1):56-66. 
 
4. O’Neill, J. (2014). Antimicrobial Resistance: Tackling a Crisis for the Future Health and Wealth of Nations. HM Government. Accessed in:  
https://wellcomecollection.org/works/rdpck35v  
 
5. CDC. Antibiotic Resistance Threats in the [LOCATION_002], 2019. Atlanta, GA: U.S. Department of 
Health and Human Services, CDC (CDC 2019); 2019.  Accessed in:  
https://www.cdc.gov/drugresistance/pdf/threats-report/2019- ar-threats -report -508.pdf 
 
6. O’Connor S, Lam LKT, Jones ND, Chaney MO. Apramycin, a unique aminocyclitol antibiotic. L 
Org Chem 1976; 41 (12): 2087-2092.  https://doi.org/10.1021/jo00874a003  
 
7. Apramycin. Summary Report (2). The European Agency for the Evaluation of Medicinal 
Products, Veterinary Medicines Unit. January 1999. (EMA 1999). Accessed in: https://www.ema.europa.eu/en/documents/mrl- report/apramycin -summary -report-2- committee -
veterinary -medicinal -products_en.pdf 
 
8. EU Commission Press Release IP/05/1687. Ban on antibiotics as growth promoters in animal feed 
enters into effect. Brussels, 22 December 2005. Accessed in: http://europa.eu/rapid/pressrelease_IP -05-1687_en.htm 
 
9. FDA Drugs with Veterinary Feed Directive (VFD) Marketing Status (FDA 2021 ). Accessed in:  
 https://www.fda.gov/animal-veterinary/development-approval-process/drugs- veterinary -feed-
directive- vfd-marketing -status 
  
10. Investigator’s Brochure , EBL -1003 (apramycin). V8.0, Juvabis AG, [ADDRESS_601774]. Dis., 2016 Dec; 86, 439-441 
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601775] multidrug -, carbapenem - 
and aminoglycoside- resistant Enterobacteriaceae and Acinetobacter baumannii . J Antimicrob 
Chemother 2019; 74: 944–952. doi:10.1093/jac/dky546 
 
13. Kang AD, Smith. KP, Eliopoulos GM, Berg AH, McCoy C, Kirby [CONTACT_73122]. Invitro Apramycin 
Activity against multidrug -resistant Acinetobacter baumannii and Pseudomonas aeruginosa. 
Diagn. Microbiol. Infect. Dis., 2017 Jun; 88(2) 188- 191. 
 
14. Truelson KA, Brennan-Krohn T, Smith KP, Kirby [CONTACT_73122]. Evaluation of apramycin activity against 
methicillin -resistant, methicillin -sensitive, and vancomycin- intermediate Staphylococcus aureus 
clinical isolates. Diagn Microbiol Infect Dis [ADDRESS_601776]; 92(2):168-171. doi:10.1016/j.diagmicrobio.2018.05.018.  
 
15. Becker  K, Aranzana- Climent  V, Cao  S, Nilsson  A, Shariatgorji  R, Haldimann  K, Bjorn Platzack  
B, Hughes D, Per E. Andren  PE, Bottger  EC, Friberg LE, Hobbie SN, on behalf of the ENABLE 
consortium. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clinical Microbiology and Infection 2021 Sept; 27(9):1315 -1321.  
https://doi.org/10.1016/j.cmi.2020.12.004  
 
16. Matt T, Ng CL, Sha SH, Akbertenov R, Shcherbakov D, Meyer M, et al. Dissociation of 
antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2- 
deoxystreptamine apramycin. Proc. Natl. Acad. Sci. U S A, 2012 Jul 3;109(27):[ZIP_CODE]-9. doi: 
10.1073/pnas.[PHONE_9818] 
 
17. Ishikawa M, García- Mateo N, Čusak  A, López- Hernández I, Fernández- Martínez M, Müller M, 
et al. Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and 
apramycin as promising antibiotics for clinical use. Sci Rep. 2019 Feb 20;9(1):2410. 
 
18. Mingeot- Leclercq, M -P, Glupczynski Y, and Tulkens PM. Aminoglycosides: Activity and 
Resistance. Antimicrob Agents Chemother. 1999 Apr; 43(4): 727–737. DOI: 
10.3390/ijms21176133 
 
19. Plattner M, Gysin M, Haldimann K, Becker K, Hobbie SN. Epi[INVESTIGATOR_50123], Phenotypic, and Structural Characterization of Aminoglyco side-resistance Gene aac(3) -IV. Int J Mol Sci 2020 
Aug 25; 21(17) : 6133. DOI: 10.3390/ijms21176133 
 
20. Böttger EC, Crich D. Aminoglycosides: Time for Resurrection of a Neglected Class of Antibacterials? ACS Infect Dis. 2020 Feb  14; 6(2): 168–172.  doi:10.1021/acsinfecdis.9b00441. 
 
21. Sou T, Hansen J, Liepi[INVESTIGATOR_469371]  E, et al. Model-Informed Drug Development for Antimicrobials: 
Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin. 
Clinical Pharmacology and Therapeutics 2021 ; 109(4); 1063-1073. doi:10.1002/cpt.2104 
 
22. Zhang W , Yi Huang  Y, Helmers R . Bronchoalveolar Lavage. Chapter 14 in F lexible 
Bronchoscopy, Book Editor(s):  Ko-Pen Wang MD, Atul C. Mehta MD, FACP, FCCP, J. Francis 
Turner Jr. MD, FACP, FCCP, FCCM 4th edition, 08 May 2020, Wiley Online Library | https://doi.org/10.1002/9781119389231  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  [ADDRESS_601777] 2004; 125:  945–52. 
 
24. Dezube R. Bronchoscopy. Merch Manuals, May 2021  
Accessed at https://www.merckmanuals.com/professional/pulmonary -disorders/diagnostic- and-
therapeutic-pulmonary-procedures/bronchoscopy  
 
25. Levey AS, Stevens LA. Estimating GFR using the CKD Epi[INVESTIGATOR_10444] (CKD- EPI) 
creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better 
risk predictions. Am J Kidney Dis. 2010; 55(4):622-627.  
https://doi.org/10.1053/j.ajkd.2010.02.337  
 
26. Tenero D, Bowers G, Rodvold KA, Patel  A, Kurtinecz K, Dumont E, Tomayko J , Patel  P. 
Intrapulmonary Pharmacokinetics of [COMPANY_004]2251052 in Healthy Volunteers. Antimicrob  Agents 
Chemother 2013 ; 57(7): 3334-3339 | DOI: 10.1128/AAC.[ZIP_CODE]-12 
 
27. Gotfried MH, Horn K, Garrity -Ryan L, Villano S, Tzanis E, Chitra S, Manley A, Tanaka SK, 
Rodvold KA. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, 
epi[INVESTIGATOR_71444], and alveolar cells of healthy adu lt subjects. Antimicrob Agents Chemother 
2017; 61:e01135-17. https://doi.org/10.1128/AAC.[ZIP_CODE]-17 
 
28. Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Bi S, Chavez-Eng CM, Zhang 
Z, Butterton JR. Intrapulmonary pharmacokinetics of relebactam, a novel β -lactamase inhibitor, 
dosed in combination with imipenem -cilastatin in healthy subjects. Antimicrob Agents 
Chemother 2018; 62:e01411 -17. https://doi.org/10.1128/AAC.[ZIP_CODE]-17 
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
DMID/NIAID/NIH 
CONFIDENTIAL  99 18 APPENDICES
DMID Protoco20-0012SMIS  Version 5.0 
Apramycin   10 July 2023  
 
DMID/NIAID/NIH 100 
CONFIDENTIAL   Appendix A: Schedule of Study Procedures and Evaluations  
Table 1: Schedule of Events  
Procedures and Evaluations  Out- 
patient  In- 
patient  In- 
patient  Treatment Period (In -patient)  Follow -up  
(out-patient)  
Early 
Termina -
tion Unsche -
duled  Day -28  
to -3 Day -2 Day -1 Day 1 Day 2 Day 3 
Day 14  
 (± 3 
days) Day 30  
(±4 
days) Screening 1 Check -
in Baseline  Pre-
dose  0 h 
(dose)  0.5 h  
(±5 
min)  1 h  
(±5 
min)  2 h  
(±5 
min)  4 h  
(±10 
min)  8 h 
(±15 
min)  16 h 
(±15 
min)  24 h 
(±1 
h) 36 h  
(±1  
h) 48 h 
(±1 
h) 60 h 
(±1 
h) 
Informed consent  X                   
Demographics X                   
Inclusion and exclusion criteria  X 2                   
Review of Inclusion and exclusion criteria  3  X 3 X 3 X 3                
Medical history (including family history of auditory loss , 
renal disorders and sudden death ) X                   
Medical History update 4  X 4 X 4 X 4                
Prior medication  X X X X                
Concomitant medication      X X X X X X X X X X X X X X X 
Complete Physical examination (PE)  X X             X X  X  
Abbreviated PE    X                 
Symptom -directed  (Focused ) PE    X X X X X X X X X X X X  X X X 
Vital signs (BP, HR, RR, T) 5 X X X X  X X  X  X X X X X X  X X 
Height, Weight, BMI calculation  X                   
Weight  X              X  X  
Spi[INVESTIGATOR_038] (FEV1 and FEV1/FVC)  X                   
12-lead ECG (single recording) 6 X X          X X X X X  X X 
12-lead ECG (triplicate recording)[ADDRESS_601778]  X X                  
Urine drug toxicity and cotinine tests X X                  
Clinical laboratory  tests 9 X X  X        X  X  X  X X 
Calculation of glomerular filtration rate (CKD -EPI) [ADDRESS_601779] (females only)  X                   
Serum FSH (post -menopausal females only)  X                   
Urine pregnancy test (females only)   X                  
Blood sample for exploratory biomarkers [ADDRESS_601780], tympanometry, stapedial 
reflexes14 X                   
Ear otoscopy14  X            X X X X  
Ear audiometry and otoacoustic tests 14 X X            X X X X  
Admission 15  X                  
Enrollment and Assignment to T cohorts 16   X                 
Discharge 17               X     
IV administration of apramycin 18     X-------21
              
DMID Protoco20-0012SMIS  Version 5.0 
Apramycin   10 July 2023  
 
DMID/NIAID/NIH 101 
CONFIDENTIAL   Check of infusion site      X X X    X X X X X X  X  
Treatment - emergent adverse events (TEAE) and serious 
AEs (SAE s) 19     X X X X X X X X X X X X X X X 
Blood (plasma) sampling for apramycin PK [ADDRESS_601781] 21      X       X       
Administration of sedative or anesthetic medication 22      X  X X X  X        
Bronchoscopy /BAL (for ELF and AM PK)  23      X  X X X  X        
Oxygenation support (TBC)      X X X X X X X X        
Drinking schedule 24     X X X X X X X X X X    X  
Counseling 25 X X X X X X X X X X X X X X X X  X  
1. Screening including Ear -Nose -Throat (ENT)/Audiology assessments are planned to be completed in a single Screening Visit. If schedule cannot be accommodated, 
ENT/Audiology assessments will be completed on a second visit within the screening period.  
2. Inclusion and exclusion criteria regarding ENT/Audiology assessments to be reviewed by [CONTACT_159564].  
3. Review of inclusion and exclusion criteria on Day - 2 to determine eligibility for admission ; on Day - 1, before 12-lead ECG, to determine eligibility for enrollment; and 
on Day [ADDRESS_601782] remains eligible for dosing . 
4. Medical history update to include pre -dose events.  
5. Vital signs include systolic and diastolic BP, heart rate, respi[INVESTIGATOR_206819].  
6. 12-lead ECG single recording with 10 sec rhythm strip.   
7. 12-lead ECG: triplicate safety ECGs with 10 sec rhythm strip s on Day -1 at the same timepoints as the projected timepoints for ECGs to be recorded on Day 1, and on 
Day 1  within 30 min of dosing, and at 1h (± 5 min ), 4h (± 10 min ) and 16 h (± 15 min) after start ing the apramycin dose.  Record ECG before VS and PK draws and, at 
[ADDRESS_601783] -dosing, before administration of sedation or anesthetic for BAL in cohort T3.   
8. Hepatitis B surface antigen (HBsAg), hepatitis virus C antibody (HCV) and human immunodeficiency virus (HIV) antibody.  
9. Clinical laborator y tests under fasting conditions: hematology, coagulation, and clinical chemistry panels  and thyroid stimulating hormone (TSH) & free T3/free T4. (S ee 
Section 8.2.1) 
10. The CKD -EPI [INVESTIGATOR_10908], expressed as a single equation, is GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1) -1.209 × 0.993Age × 1.018 [if female] _ 1.159 [if black], where 
Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and - 0.411 for males, min indicates the minimum of Scr/κor 1, and max indicates 
the maximum of Scr/κ or 1 [Levey 2009].(Formula will be used and result will be included in the lab report)  
11. Urinal ysis (UA) by [CONTACT_5230]. If abnormal for blood, protein and glucose, perform microscopic UA. The results of microscopic UA supe rsede those of UA by [CONTACT_5230]. UA 
may be postponed in a menstruating female. Abnormal UA in a menstruating female is not graded as a TEAE; the UA should be completed after the end of menstruation.  
12. Cystatin C in serum.  
13. Kidney-injury molecule 1 (KIM -1) in urine.  
14. Ear otoscopy, Valsalva test, tympanometry, stapedial reflexes , and pure-tone audiometry with standard frequencies and distortion product otoacoustic emissions 
(DPOAEs) at screening. Ear otoscopy, and p ure-tone audiometry including high frequencies and DPOAEs at check-in (Day -2 [or Day -4 or Day -3 if needed] ) and at 
Days 3  (+2 days) , 14 (± 3 days), and 30 (± 4 days) , or ET . 
15.  Subjects will be admitted to the ward on Day -2 after confirmation of eligibility . 
16. Assignment to Lung PK timepoint cohorts (T1 – T5) and Enrollment to be performed before 12-lead ECG on Day -1 . – Subjects with ECGs on Day -1 and pre -dose on 
Day 1 with clinically significant abnormalities according to the PI [INVESTIGATOR_469372] d be withdrawn and replaced.  
17. Subjects may be discharged from the CTU after Day 3 collection of the 60-h plasma PK sample. 
18.  Duration of apramycin infusion is 30 ± 5 min.  
19. Adverse events from the start of dosing to the end of the trial are considered treatment -emergent adverse events (TEAE) or serious AEs (SAE).  
20. Blood samples for plasma PK are taken  pre-dose, and at 30 (± 5) minutes  (end of infusion) and 1 h (±5 min), 2 h (±5 min), 4 h (±10 min), 8 h (±15 min), 16 h (±15 min), 
24 h (±1 h), 36 h (±1 h), 48 h (±1 h) and 60 h (±1 h) after start of the infusion - Blood samples for plasma PK are taken at the nominal timepoints. If collecti on of BAL is 
delayed, plasma PK will be collected at the nominal timepoint and again within [ADDRESS_601784] BAL sample. In that case, total apramycin concentration 
will be measured in both samples, but only the drug concentration in the delayed plasma PK sample will be used to calculate the Lung PK/Plasma PK ratio.   
21. A protein binding test for the measurement of free apramycin will be performed using aliquots of plasma PK samples collected at 0.5 h (± 5 min) and 36 h (± 1 h) after 
start of  infusion.  
22. Type of sedation or light anesthesia m edication for bronchoscopy/BAL procedure and local anesthetic TBD by [CONTACT_469445] s. 
23. Each subject is assigned to a single bronchoscopy/BAL procedure. Lung PK samples (for measurement of total apramycin concentration) after initiation of infusion and 
corresponding cohorts (T) are: (Cohort T1), 30 min (±5 min); (Cohort T2), 2 h (±5 min); (Cohort T3), 4 h (±10 min); (Cohort T 4), 8h (± 15 min); and (Cohort T5), 24 h 
(± 1 h) . Lung PK timepoints are aligned with plasma PK samples  collected for the measurement of total apramycin concentration at 30 min  (±5 min) , 2 h (±5 min) , 4 h 
(±10 min) , 8 h (±15 min) and 24 h (±1 h)  after start of apramycin infusion,  If BAL is delayed, plasma sample will be collected at the nominal timepoint and again  within 
[ADDRESS_601785] BAL sample collection. Urea will be measured at the same timepoints in plasma and BAL (ELF) samples.  
24. Subjects to be kept hydrated water starting 30 min before until 24 h after start of infusion (document time and volume of wat er intake).  
25. Provide counseling at the end of each encounter with the subject. Counsel on use of contraception (males and females), avoidance of pregnancy  
(women of childbearing potential), avoidance of sperm donation, and avoidance of prohibited medications , illicit dru gs, alcohol, nicotine products, vigorous exercise, and 
exposure to loud noises.  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 102 
CONFIDENTIAL   Appendix B: Adverse Events Toxicity Grading Criteria  
ABBREVIATIONS : Abbreviations utilized in the Tables: 
ADL = Activities of Daily Living   
CTU = Clinical Trial Unit 
ULN = Upper Limit of Normal IV    = Intravenous  
      
ESTIMATING SEVERITY GRADE  
For abnormalities NOT found elsewhere in the Toxicity Tables, use the scale below to 
estimate grade of severity:  
GRADE 1  Mild  Events require minimal or no treatment; do not interfere with the 
subject’s daily activities.  
GRADE 2  Moderate  Events result in a low level of inconvenience or concern with 
therapeutic measures ; may cause some interference with 
functioning.  
GRADE [ADDRESS_601786]’s usual daily activity and may require 
systemic drug therapy or other treatment; are usually 
incapacitating.  
SERIOUS OR LIFE -THREATENING AEs  
Clinical events considered to be serious or life-threatening include, but are not limited to  
seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, and severe depression.  
COMMENTS REGARDING THE USE OF THESE TABLES  
• Standardized and commonly used toxicity tables (Division of AIDS, National Cancer Institute [NCI] Common Toxicity Criteria [CTC], and World Health Organization 
[WHO]) have been adapted for use by [CONTACT_421237] (DMID) and modified to better meet the needs of subjects in DMID trials.  
• For parameters not included in the following Toxicity Tables, the CTU will refer to the “Guide for Estimating Severity Grade” located above.  
• Criteria are generally grouped by [CONTACT_6764].  
Some protocols may have additional protocol specific grading criteria, which will supersede 
the use of these tables for specified criteria.
 
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 103 
CONFIDENTIAL   Note 1:   No recent hot or cold beverages or smoking. A protocol should select either 0C or 0F for inclusion  
Note 2 :  Assume awake and in supi[INVESTIGATOR_19636] [ADDRESS_601787] 3 times with 2 
concordant results (See Section 8.1.6)  
Note 3 :   Abnormal HR and BP on first measurement may be repeated twice more with the subject resting between 
measurements for at least 5 min (See Section 8.1.6) . 
Note 4 :   Exceptions to screening BP and HR reference  range are:  
(a) Subjects with baseline HR ≥ [ADDRESS_601788] symptomatic bradycardia, 
includin g syncope, heart disease, ECG abnormalities, or history of syncope or use of medication  
(b) Subjects with baseline SBP up to [ADDRESS_601789] MH of symptomatic hypertension, including paroxysmal hypertension, heart disease, renal disease, CNS disease, visual abnormalities or evidence of peripheral vascular disease, ECG abnormalities, use of 
medication, use of illicit drugs or FH of hypertension  
Note 5 :   Isolated/individual abnormalities of VS would not be considered toward halting criteria. Abnormalities of 
VS will be described as “increased X” or “decreased X” (X = HR, BP, RR, temperature) if asymptomatic, 
transient and not associated with a systemic or organ- specific disorder and coded by [CONTACT_469446] (SOC) “Investigations.” These abnormalities will be graded per criteria in this table, 
but not considered in determining whether study stoppi[INVESTIGATOR_105308]. On the other hand, 
abnormalities of VS that are either secondary to s ystemic or organ- specific clinical syndrome or primary 
disorders will be coded in the appropriate SOC (e.g., “ cardiac disorders ”, “respi[INVESTIGATOR_17744] ”, 
“immunological disorders ”, etc). These abnormalities will be considered in determining whether stoppi [INVESTIGATOR_469373] .  Table 2: Toxicity Grading Tables – CLINICAL AEs  
Clinical AEs  Reference range  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
VITAL SIGNS 1     
Fever - °C 
Fever  - °F 36.1 - 37.2 1 
97.0 - 99.0 1 37.3 - 38.4 
99.1 - 101.1  38.5 - 38.9 
101.2 - 102.0  >38.9  
>102.0  
Tachycardia - bpm 50 - 100 2,3,4,5  101 - 115 116 - 130 >130 or ventricular 
dysrhythmias  
Bradycardia – bpm 45 - 49 40 - 44 <40 
Hypertension (systolic) 
- mmHg  130/89 2,3,4,5  131 - 150 151 - 160 >160  
Hypertension (diastolic) 
- mmHg  90 - 95 96 - 100 >100  
Hypotension (systolic) - 
mmHg  85 - 88 80 - 84  <80 
Tachypnea – breaths 
per min  10 - 20 2,3,4,5  21 - 25 26 - 30 >30 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 104 
CONFIDENTIAL    
Table 2: Toxicity Grading Tables – CLINICAL AEs  
Clinical AEs  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
CARDIOVASCULAR  
Arrhythmia   
Asymptomatic or transient 
signs; no medical 
intervention required. Recurrent and/or persistent 
signs; symptomatic medical 
intervention required. 
Hemorrhage Estimated blood loss 
<100 mL. Estimated blood loss 
>100mL; no transfusion 
required . Blood transfusion required. 
RESPI[INVESTIGATOR_469374] h no treatment 
required . Persistent cough treatment 
required . Interferes with daily 
activities . 
Bronchospasm, Acute  Transient bronchospasm no 
treatment required; FEV1 71 -
80% of predicted peak flow . Requires treatment; 
normalizes with 
bronchodilator; FEV1 60-
70% of predicted peak flow . No normalization with bronchodilator; FEV1 <60% 
of predicted peak flow . 
Dyspnea   Does not interfere with usual 
and social activities . Interferes with usual and 
social activities; no treatment. Prevents usual and social 
activities OR requires 
treatment . 
EAR AND LABY[CONTACT_469447]  
 
(Adult enrolled on a 
Monitoring Program (on a 1, 
2, 4, 3, 6, and 8 kHz 
audiogram)  Threshold shift of [ADDRESS_601790] one 
ear. Threshold shift of >[ADDRESS_601791] one 
ear. Threshold shift of >[ADDRESS_601792] one 
ear; therapeutic intervention 
indicated . 
Tinnitus  Mild symptoms intervention 
not indicated . Moderate symptoms; limiting 
instrumental ADL. Severe symptoms; limiting 
self-care ADL . 
Vertigo  Mild symptoms . Moderate symptoms; limiting 
instrumental ADL . Severe symptoms; limiting 
self-care ADL . 
GASTROINTESTINAL   
Nausea  No interference with normal 
activity . Some interference with 
normal activity . Prevents daily activities . 
Vomiting  No interference with activity 
OR 1 -2 epi[INVESTIGATOR_11630] a 24- h 
period . Some interference with 
activity OR >2 epi[INVESTIGATOR_11630] a 
24-h period. Prevents daily activity OR 
requires medical intervention . 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 105 
CONFIDENTIAL    
Table 2: Toxicity Grading Tables – CLINICAL AEs  
Clinical AEs  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Diarrhea  2-3 loose or watery stools in 
a 24-h period. 4-5 loose OR watery stools in 
a 24-h period. 6 or more loose or watery 
stools in a 24- h period OR 
requires IV hydration OR 
requires medical intervention . 
Oral Discomfort / Dysphagia  Mild discomfort; no difficulty 
swallowing . Some limits on eating 
/drinking . Eating/talking very limited; 
unable to swallow solid 
foods . 
LOCAL IV CATHETER REACTION 
IV site reaction  Not applicable . Erythema with associated 
symptoms (e.g., edema, pain, 
induration, phlebitis) . Ulceration or necrosis; severe 
tissue damage; operative 
intervention indicated . 
SYSTEMIC REACTIONS  
Anaphylaxis **  -- -- Symptomatic bronchospasm, 
with or without urticaria; 
parenteral intervention 
indicated; allergy -related 
edema or angioedema;  
hypotension . 
**Definition : A disorder characterized by [CONTACT_364307] -
like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis, and loss of consciousness, and may lead to death.  
Allergic Reaction  Pruritus without rash . Localized urticaria OR 
requires oral therapy . Generalized urticaria OR 
angioedema OR anaphylaxis 
OR requires epi[INVESTIGATOR_469375] (including drug fever)  Transient flushing or rash; 
temperature 38.0 -38.4°C 
(100.4- 101.1°F) . Rash; flushing; urticaria; 
dyspnea; temperature 38.5 - 
38.9°C (101.2 – 102.0°F) . Symptomatic 
bronchospasm with or 
without urticaria; parenteral 
medication indicated;  
allergy -related edema or 
angioedema; hypotension; 
temperature >38.9°C 
(>102.0°F) .  
Headache  No interference with activity . Repeated use of non -narcotic 
pain reliever for more than 24 
h OR some interference with 
activity . Significant; any use of 
narcotic pain reliever OR 
prevents daily activity OR 
requires triptans . 
Fatigue  No interference with activity . Some interference with 
activity . Significant; prevents daily 
activity . 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 106 
CONFIDENTIAL    
Table 2: Toxicity Grading Tables – CLINICAL AEs  
Clinical AEs  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Myalgia  No interference with activity . Some interference with 
activity . Significant; prevents daily 
activity . 
SKIN  
Mucocutaneous  Erythema, pruritus . Diffuse, maculo -papular rash, 
dry desquamation. Vesiculation  OR moist 
desquamation OR ulceration . 
Pruritus No or minimal interference 
with usual social and 
functional activities .  Greater than minimal 
interference with usual social 
and functional activities .  Inability to perform usual 
social and functional daily 
activities . 
ALL OTHER CONDITIONS  
Illness or clinical AE (as 
defined according to 
applicable regulations)  Require minimal or no 
treatment; does not interfere 
with the subject’s daily 
activities.  Result in a low level of 
inconvenience or concern 
with therapeutic measures; 
may cause some interference 
with functioning.  Interrupt a subject’s usual 
daily activity and may require 
systemi c drug therapy or 
other treatment; are usually 
incapacitating . 
  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 107 
CONFIDENTIAL   Table 3: Toxicity Grading Tables – LABORATORY AEs  
Laboratory AEs Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Blood, serum, or plasma *  
HEMATOLOGY     
Hemoglobin decrease, female – 
g/dL  9.6 – 11.0 8.0 – 9.5 <8.0 
Hemoglobin decrease, male – 
g/dL  11.0 – 12.9 8.5 – 10.9 <8.5 
WBC increase – x103/ µL >10.8 – 15.0 >15.0 – 20.0 >20.0  
WBC decrease – x103/ µL 2.4 – <3.4 1.4 – <2.4 <1.4 
Neutrophils decrease – x103/ µL 1.0 – <1.4 0.75 – <1.0 <0.75  
Lymphocytes decrease – x103/ µL <0.7 –0.4 <0.4 – 0.3 <0.30  
Monocytes increase – x103/ µL >0.9 – 2.0 >2.0 – 3.0 >3.0 
Eosinophils increase – x103/ µL >0.4 – 0.75 >0.75 – 1.0 >1.0 
Basophils increase – x103/ µL >0.2 – 0.5 >0.5 – 0.8 >0.8 
Platelets decrease – x103/ µL 90 – <150  55 – <90 <55 
COAGULATION     
PT INR ratio  >1.2 – 1.8 >1.8 – 2.1 >2.1 
Prothrombin Time (PT) - seconds  >12.0 – 15.0 >15.0 – 18.6 >18.6  
Activated Partial Thromboplastin 
Time (APTT) - seconds  >33.0 – 54.0 >54.0 – 75.0 >75.0  
CHEMISTRY     
Sodium decrease – mmol/L  130 - 133 124 –129 <124  
Sodium increase – mmol/L  145 - 150 151 – 156 >156  
Potassium increase – mmol/L  5.3 – 6.0 6.1 – 6.5 >6.5 
Potassium decrease – mmol/L  3.4– 3.0  2.5 – 2.9 <2.5 
Total Carbon Dioxide (CO 2) 
increase  – mmol/L  30 - 35 36 - 37 >37 
Total Carbon Dioxide (CO 2) 
decrease – mmol/L  17 - 19 14 - 16 <14 
Calcium decrease – mg/dL  7.8 – 8.6 7.0 – 7.7 <7.0 
Calcium increase – mg/dL  10.3 – 11.4 11.5 – 12.5 >12.5  
Magnesium decrease – mg/dL  1.2 – 1.5 1.1 – 0.9 <0.9 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 108 
CONFIDENTIAL   Table 3: Toxicity Grading Tables – LABORATORY AEs  
Laboratory AEs Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Blood urea nitrogen (BUN) 
increase, 18 -39Y - mg/dL  21 - 58 59 – 120 >120  
Blood urea nitrogen (BUN) 
increase, 40 -59Y – mg/dL  25 - 58 59 – 120 >120  
Glucose decrease, fasting – 
mg/dL  55 - 69 40 – 54 <40 
Glucose increase, fasting – mg/dL  100 – 160 161 – 250 >250  
Creatinine increase, male – mg/dL  1.28 – 1.90 1.91 – 3.80 >3.80  
Creatinine increase, female – mg/dL  0.58 – 1.50 1.51 – 3.00 >3.[ADDRESS_601793] bilirubin  0.41 – 0.70 0.71 – 1.20 >1.20  
Total bilirubin (serum) increase – 
mg/dL  (with other LFTs in the 
normal range)  1.3 – 2.0 2.1 – 2.5 >2.5 
Total bilirubin (serum) increase – 
mg/dL  (accompanied by a >[ADDRESS_601794])  1.3 – 1.7 1.8 – 2.4 >2.4 
Total protein decrease – g/dL  5.1 – 5.9 4.6 – 5.0 <4.6 
Albumin, decrease, Male, 18 -30Y 
- g/dL  4.0 – 3.0 2.0– 2.9 <2.0 
Albumin decrease, Female,  
18-30Y – g/dL  3.8 – 3.0 2.0– 2.9 <2.0 
Albumin decrease, Male,  31-50Y – g/dL  3.9 – 3.0 2.0– 2.9 <2.0 
Albumin decrease, Female,  31-50Y – g/dL  3.7 – 3.0 2.0– 2.9 <2.[ADDRESS_601795] increase – U/L 41 – 80 81 – 120 >120  
ALT increase, male – U/L 45– 88 89 - 132 >132  
ALT increase, female – U/L 33 – 64 65 – 96 >96 
Alkaline phosphatase (AP) 
increase, males 18 -20Y – U/L 126 – 250 251 – 375 >375  
Alkaline phosphatase (AP) 
increase, females, 18 -20Y – U/L 107 – 250 251 – 375 >375  
Alkaline phosphatase (AP) 
increase, 21 -150Y – U/L 122 – 250 251 – 375 >375  
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 109 
CONFIDENTIAL   Table 3: Toxicity Grading Tables – LABORATORY AEs  
Laboratory AEs Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Urine  
URINALYSIS by 
[CONTACT_469448]  1+ 2+ >2+ 
Blood (occult)  1+ 2+ >2+ 
Glucose  1+ 2+ >2+ 
URINE 
MICROSCOPY     
Red blood cells (RBC) per HPF  3-10 11-30 >30 and/or gross blood  
White blood cells (WBC) per 
HPF 6-10 11-30 >30 and/or symptomatic 
urogenital infection  
Bacteria (microscopic)  few moderate  many  
Note 1:  With the exception of AST, ALT, AP, bilirubin, electrolytes, urine protein, BUN and creatinine, which should be within 
reference range, lab values of other analytes in the grade 1 range are acceptable for enrollment if (a) they are not considered to be clinically significant by [CONTACT_1755] (b) there is no cluster of abnormal labs that combined are 
suggestive of an underlying disorder.  
Note 2 : Other Exceptions to screening laboratory tests’ normal reference ranges are:  
a. Racially based low total W BC or neutrophil counts up to toxicity Grade 1 are allowed, but toxicity Grades 2 or 3 are 
exclusionary.  
b. Labs performed as part of a panel but not listed above are to be recorded in the database. If abnormal, they are not 
exclusionary and are not to be graded per Toxicity table, however, the investigator would make a clinical decision 
about their clinical significance and, if clinically significant, they will be graded according to the criteria in 
Section  9.2.1  . (Examples include mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and nucleated red blood cell count (NRBC CT), which are included in a CBC with differential.)  
Note 3 : If a subject was accepted into the trial with a laboratory value of an analyte that overlaps with values used for grading 
Grade 1 laboratory abnormalities, a TEAE will be reported if the on -study value of the same analyte increases to 
Grade 2 or higher . 
Note 4 : If the dipstick UA is abnormal, a microscopic UA will be performed, and the results will supersede the results of the 
dipstick UA.  
Note 5:  Menstruating females with a positive dipstick UA or microscopic UA may be retested following cessation of menses . 
Note 6: Isolated laboratory values that are outside the range of eligibility but are thought to be due to an acute condition or due 
to collec tion or laboratory error may be repeated once.  
 
 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 
 
DMID/NIAID/NIH 110 
CONFIDENTIAL   Table 4: Toxicity Grading Tables – ECG  
ECG interval 
abnormality  Reference 
range  Grade 1  Grade 2  Grade 3  
QTcF interval prolonged (msec):  
• Male 
• Female  •   ≤ 450 msec  
•   ≤ 470 msec Asymptomatic,  
QTcF  
• 451  ̶  479 msec  
• 471  ̶  479 msec Asymptomatic,  
QTcF 480 -500 msec  
OR  
increase in interval 30 -
59msec above baseline  Asymptomatic,  
QTcF >500 msec  
OR 
increase in interval 
≥60 msec above baseline  
PR interval prolonged (msec)  ≤210 msec  211-250 msec >250 msec Type II 2
nd degree AV 
block  
OR  
ventricular pause >3.0 sec  
Note 1: E vents will be coded as treatment -emergent SAEs if there are life -threatening associated symptoms or signs (arrhythmia, 
CHF, hypotension, syncope, TdP, etc.) . 
Note 2 : If a male subject was accepted into the trial with a QTc F value that overlaps with values used for grading Grade 1 QTc F 
prolongation, a  TEAE  will be reported if the QTc F value is higher than the baseline  value. 
DMID Protocol 20-0012  Version 5.0 
Apramycin  10 July 2023  
 _____________________________________________________________________________________________________________________________________________  
 _____________________________________________________________________________________________________________________________________________  
DMID/NIAID/NIH   111 
CONFIDENTIAL   Appendix C: Blood Volume Withdrawn During the Trial  
Table 5: Laboratory Samples and Estimated Total Blood Volume (mL)  
Study Periods  Out-
patient  In-
patient   In-
patient  In-patient Dosing Period (Days 1 – 3) Out-patient  
ET Study Visit  Screen  Check -
in Baseline  Dosing  Follow -up Discharge Follow -
up Final  
Study Day  a -28 to -3 -2 -1 1 2 (24 h)  2 (36 h)  3 (48 h)  3 (60 h ) 14 (± 3 
days ) 30 (± 4 
days ) 
HEMATOLOGY 1 4.0 4.0  4.0 4.0 4.0 4.0 4.0 4.0  4.0 
CHEMISTRY and serum β -HCG and FSH 1 8.5 8.5  8.5 8.5 8.5 8.5 8.5 8.5  8.5 
COAGULATION 1 2.7 2.7  2.7 2.7 2.7 2.7 2.7 2.7  2.7 
TSH, Free T4, Free T3 1 3.5 3.5  3.5 3.5 3.5 3.5 3.5 3.5  3.5 
Viral Serology (HIV, HBsAg, HCV) 2 7.0           
Exploratory Marker  (serum Cystatin) 3  3.5  3.5   3.5  3.5 3.5 3.5 
PK 4    56.0 8.0 8.0 8.0 8.0   8.0 
Total volume/visit  25.7 22.2 0 78.2 26.7 26.7 30.2 26.7 22.2 3.5 30.2 
Cumulative total volume  25.7 47.9 47.9 126.1  152.8  179.5  209.7  236.4  258.6  262.1   
a Study Days shown correspond to days in each study  period. For a view of the cumulative numbering of study days, please refer to Section  7. 
1 Clinical Safety  blood tests (HEM, CHEM , COAG , TSH, fT4, fT3) are drawn  at Screening  Visit , on Day -2, and on Day s 1, 2, 3 and 14  (± 3 days) , or ET.  Serum pregnancy test 
in all women is drawn at Screening . FSH is drawn only at Screening in post -menopausal women.  
[ADDRESS_601796] is drawn on Day -2, Day 3 (at 48 h) and Day 14  (± 3 days) . 
4 PK plasma samples are drawn on Day 1 (30 min before dosing and at 0.5, 1, 2, 4, 8,  16 h after dosing); on Day 2  (24 and 36  h after dosing) and on Day 3 ( 48 and 60 h after 
dosing), or ET  if occurs within 24 h of dosing . 